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reside in a low-perfusion niche and depend on local signals to survive and to maintain the capacity for
self-renewal. HSCs removed from the niche can survive if they receive hematopoietic cytokines, but they
then lose the ability to self-renew. However, we showed previously that simultaneous inhibition of
glycogen synthase kinase-3 (GSK-3) and mammalian target of rapamycin complex 1 (mTORC1) maintains
HSC function ex vivo without the need for exogenous cytokines. As these experiments were initially done
in heterogeneous cell populations, I then showed that purified HSCs can also be maintained under these
conditions, demonstrating a direct effect of GSK-3 and mTORC1 inhibition on HSCs. Although Wnt/βcatenin signaling downstream of GSK-3 is required for this response, the downstream effectors of this
network remained otherwise undefined. I therefore explored targets downstream of GSK-3 and mTORC1. I
found that HSCs express a pro-autophagic gene signature and accumulate LC3 puncta only when both
mTORC1 and GSK-3 are inhibited, identifying autophagy as a signature for a signaling network that
maintains HSCs ex vivo. In contrast, I did not find evidence to support a role for other downstream targets
of mTORC1, such as protein translation and mitochondrial biogenesis. I also report a significant reduction
in total RNA content in cultured HSCs and describe a method to perform transcriptional profiling of these
cells. Together, these findings provide new insight into the relative contributions of various mTORC1
outputs toward the maintenance of HSC function and build upon the growing body of literature
implicating autophagy and tightly controlled protein synthesis as important modulators of diverse stem
cell populations.
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ABSTRACT
CHARACTERIZING A SIGNALING NETWORK
THAT MAINTAINS HEMATOPOIETIC STEM CELLS
Michelle Nguyen-McCarty
Peter Klein
Hematopoietic stem cells (HSCs) are able to self-renew and to differentiate into all blood
cells. HSCs reside in a low-perfusion niche and depend on local signals to survive and to
maintain the capacity for self-renewal. HSCs removed from the niche can survive if they
receive hematopoietic cytokines, but they then lose the ability to self-renew. However, we
showed previously that simultaneous inhibition of glycogen synthase kinase-3 (GSK-3)
and mammalian target of rapamycin complex 1 (mTORC1) maintains HSC function ex
vivo without the need for exogenous cytokines. As these experiments were initially done
in heterogeneous cell populations, I then showed that purified HSCs can also be
maintained under these conditions, demonstrating a direct effect of GSK-3 and mTORC1
inhibition on HSCs. Although Wnt/β-catenin signaling downstream of GSK-3 is required
for this response, the downstream effectors of this network remained otherwise
undefined. I therefore explored targets downstream of GSK-3 and mTORC1. I found that
HSCs express a pro-autophagic gene signature and accumulate LC3 puncta only when
both mTORC1 and GSK-3 are inhibited, identifying autophagy as a signature for a
signaling network that maintains HSCs ex vivo. In contrast, I did not find evidence to
support a role for other downstream targets of mTORC1, such as protein translation and
mitochondrial biogenesis. I also report a significant reduction in total RNA content in
cultured HSCs and describe a method to perform transcriptional profiling of these cells.
Together, these findings provide new insight into the relative contributions of various
mTORC1 outputs toward the maintenance of HSC function and build upon the growing
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body of literature implicating autophagy and tightly controlled protein synthesis as
important modulators of diverse stem cell populations.
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CHAPTER 1: INTRODUCTION
Introduction to hematopoietic stem cells (HSCs)
Somatic stem cells are rare populations of cells found in a range of tissues
throughout the majority of post-natal life. Distinguished by their unique capacity to both
self-renew and give rise to differentiated cell types, stem cells are essential for lifelong
tissue maintenance, both under homeostatic conditions and in response to stress or injury.
This critical function endows stem cells with vast potential therapeutic value, yet to date
their application in the clinic remains limited due in part to an incomplete understanding
of the molecular mechanisms and niche interactions that regulate stem cell function.
HSCs, which maintain the blood, are generally considered the best-characterized
stem cell population, owing to their relative accessibility and early identification in
landmark work by Till and McCulloch (1961) and others during and shortly after World
War II. Sixty years later, the HSC transplant (HSCT) is the current standard of care for a
variety of congenital and acquired hematological diseases, with over 50,000 performed
per year globally (Gratwohl et al., 2010).
However, the therapy remains plagued by rates of complications and mortality as
high as 40-50%, depending on factors such as patient age and disease stage at time of
treatment (Copelan, 2006; Juric et al., 2016). One major limitation to the success of
HSCTs is the limited availability of suitable donor cells. While it is now established that a
high level of histocompatibility matching is essential to transplant success, less than 30%
of potential transplant recipients have an HLA-matched sibling (Copelan, 2006), and
adult bone marrow donor registries currently fail to meet remaining demand.
Transplantation of umbilical cord blood (UCB) from unrelated donors has therefore
become a strategy to increase the pool of potential donors. An additional benefit of UCB
1

transplantation is that less stringent HLA-matching is necessary between donor and
recipient compared to transplantation of adult peripheral blood or bone marrow.
However, immune reconstitution is slower following UCB transplant compared to adult
HSCT (Juric et al., 2016). In addition, the number of HSCs transplanted directly correlates
with the probability of successful engraftment, and a single UCB unit contains a
suboptimal number of HSCs to reconstitute the hematopoietic system of a full-sized adult
(Hagedorn et al., 2014). Double-UCB unit transplantation accelerates neutrophil
engraftment, improves overall engraftment, and post-transplant survival compared to
single-unit transplantation. However, this strains cord blood bank resources and increases
transplant costs, and ultimately a single unit dominates engraftment (Barker et al., 2005).
The advent of targeted genome editing, such as by CRISPR/Cas9 technology, has
made gene therapy a powerful potential application for HSCTs. Gene-corrected HSCs
could be used for autologous HSCT in the treatment of monogenic hematopoietic
disorders such as sickle cell anemia, Diamond-Blackfan anemia, and severe combined
immunodeficiency. However, the relatively low efficiency of gene editing necessitates the
availability of more HSCs (Watts et al., 2011). The ability to expand and maintain HSCs ex
vivo would moreover be a powerful tool for deeper investigation of the molecular
regulation of HSCs, as well as for disease modeling and drug screening. There remains
thus a tremendous need for the ability to generate expanded numbers of HSCs.
Approaches to expand HSCs
Multiple approaches are being pursued to produce or expand HSCs. The most
direct scheme, ex vivo expansion of preexisting UCB HSCs, has yielded mixed success.
Cytokine cocktails, either alone (Zhang et al., 2008) or in combination with small
molecules (Boitano et al., 2010; Delaney et al., 2010; Chaurasia et al., 2014; Fares et al.,
2

2014), appear to achieve expansion of phenotypic and functional HSCs. Non-cellautonomous feedback signaling likely limits this expansion, as factors inhibiting HSC selfrenewal are secreted during UCB cell culture (Kirouac et al., 2010). Zandstra and
colleagues (Csaszar et al., 2012) have overcome the impact of this paracrine signaling by
demonstrating expansion of serially transplantable UCB HSCs following “fed-batch”
culture, in which culture volume is gradually, continuously increased to dilute secreted
inhibitory factors. These results are collectively promising, but cytokine-based culture
protocols likely promote expansion at the expense self-renewal, multilineage, and/or
homing function (Szilvassy et al., 2001; Hofmeister et al., 2007; Chou et al., 2010). How
robustly these advances hold true in the clinic remains to be seen.
A fundamental change in potential approaches to expand HSCs occurred when
Yamanaka and colleagues reported transcription factor (TF)-mediated reprogramming of
mouse and human fibroblasts to induced pluripotent stem cells (iPSCs) (Takahashi and
Yamanaka, 2006; Takahashi et al., 2007). Significant effort has since been invested in
directed differentiation of embryonic stem cells (ESCs) or iPSCs into HSCs. If successful,
this approach would have the additional benefit over UCB HSC expansion of allowing for
de novo generation of patient-specific HSCs for autologous transplant, thus removing the
barrier of finding an HLA-matched donor for prospective transplant recipients.
Endeavors to generate HSCs from pluripotent cells have been heavily guided by
current knowledge of embryonic development of the hematopoietic system. In the
vertebrate embryo, blood development occurs in two waves, termed primitive and
definitive hematopoiesis. The primitive program, which originates in the yolk sac, is
transient and gives rise to cells with myeloid, but not lymphoid, potential (Palis et al.,
1999). Definitive hematopoiesis is defined by the production of HSCs with full
multilineage engrafting function and arises from hemogenic endothelium of the aortic3

gonado-mesonephros (AGM) after primitive hematopoiesis (Medvinsky and Dzierzak,
1996). Hematopoietic cells derived from iPSCs are transplantable, but chimerism is very
low and/or restricted to the myeloid lineage (Lu et al., 2009; Gori et al., 2015). The limited
multilineage potential of ESC/iPSC-derived hematopoietic cells indicates a failure to
achieve definitive hematopoiesis in vitro and thus reveals incomplete recapitulation of
complex embryonic developmental signals.
Recent work by Daley and colleagues (Lu et al., 2016) achieves exciting progress
on this front. Ectopic expression of HoxB4, a TF important in early embryonic patterning
and HSC self-renewal, confers ESCs with long-term, multilineage hematopoietic
engraftment potential (Kyba et al., 2002). However, these cells exhibit a myeloid bias,
revealing the need for more robust induction of lymphoid potential. As Notch activation
provided by the AGM during definitive hematopoiesis promotes HSC specification
(Hadland et al., 2015), they added Notch ligand to their differentiation protocol and
derived HSCs with robust lymphoid as well as myeloid potential (Lu et al., 2016). This
modular approach to generating HSPCs represents a novel strategy in ongoing efforts to
engineer clinically usable HSCs.
Another approach to generate HSCs de novo has been to reprogram somatic cells
to HSCs. Bypassing a pluripotent intermediate would be an advantage because it avoids
the risk of generating HSCs contaminated with potentially teratoma-generating cells.
Successful direct conversion from one cell type to another has already been reported in
numerous therapeutically relevant cell types (Yechoor et al., 2009; Ieda et al., 2010; Son
et al., 2011), as well as between hematopoietic cell types (Xie et al., 2004; Laiosa et al.,
2006; Taghon et al., 2007). Such approaches have generally been based on combinations
of TF expression, miRNA expression, and hematopoietic cytokine exposure (Daniel et al.,
2016). This strategy led to early success in reprogramming mouse fibroblasts, revealing
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expression of Etv6, Fos, Gata2, and Gfi1b is sufficient to induce an HSC-like identity
(Pereira et al., 2013).
From a developmental perspective, endothelial cells have been an attractive
starting cell type for reprogramming to HSCs due to their close ontogenetic relationship.
Enforced expression of four TFs (FOSB, GFI1, PU.1, and RUNX1) in human umbilical-vein
endothelial cells reprograms them to a self-renewing HSC-like population capable of
multilineage engraftment in serial transplant (Sandler et al., 2014). Importantly, this
reprogramming additionally requires co-culture on an endothelial cell type that mimics
the embryonic niche. Although the reprogrammed cells possess limited lymphoid
potential, the relative success of this approach highlights the essential role of inductive
cues supplied by the niche from which HSCs arise during development.
Committed hematopoietic cells have been another promising starting point for
inducing conversion to HSCs, as in theory their hematopoietic identity may reduce the
epigenetic barriers to reprogramming. Transient expression of six TFs (Hlf, Lmo2, Pbx1,
Prdm5, Runx1t1, and Zfp37) imparts multilineage, long-term engraftment potential onto
committed mouse myeloid and lymphoid progenitors (Riddell et al., 2014). Importantly,
following transduction, the authors transplanted the cells for reprogramming to be
completed in vivo. This strategy has the dual advantage of circumventing the need to
maintain prospective induced HSCs ex vivo while also allowing the niche to provide
additional inductive cues to further promote reprogramming. One drawback to partially
in vivo induction, however, is that it impedes further characterization of the
reprogramming process.
Many hurdles remain before these substantial advances are translated into the
clinic. Each of these TF cocktails for HSC conversion bears little overlap with the others,
likely reflecting the different species and starting cell types used in each study. Whether
5

these combinations of TFs are also effective in reprogramming other cell types will be an
important question to answer. For example, fibroblasts could be preferable to blood cells
as a starting point in autologous transplant of patients with acquired hematological
disorders, as this would circumvent the need for corrective gene editing on top of
reprogramming to HSCs. Leukemogenic transformation upon reprogramming poses an
additional risk, as several of the TFs identified in the above studies are potent oncogenes.
Finally, the preservation of HSC function ex vivo has posed a notoriously difficult
challenge to the field. Maintaining HSCs once stem cell identity is achieved will therefore
not be a trivial task. The recent development of a fully-defined recombinant serum that
supports HSC culture may reduce experimental variability in these efforts (Ieyasu et al.,
2017). Combined, the outstanding questions highlight the continued need for a deeper
understanding of the mechanisms behind HSC emergence, reprogramming, and
maintenance.
Cellular characterization of the HSC niche
HSCs are capable of massive expansion in vivo, with a single stem cell able to
reconstitute the hematopoietic system long-term in a mouse (Osawa et al., 1996). The
number of transplantable HSCs in mouse bone marrow moreover increases 10-fold upon
injection into lethally irradiated recipients (Iscove and Nawa, 1997). Yet despite this
enormous potential in vivo, robust amplification of HSCs ex vivo without loss of selfrenewal capacity remains an elusive and challenging goal. The inability to induce their
expansion or generation ex vivo highlights our insufficient identification of the signals that
induce self-renewing proliferation in vivo. In-depth characterization of the HSC niche, the
local tissue microenvironment in which HSCs reside, will be a major contribution toward
defining the molecular network that regulates HSC maintenance and expansion.
6

Although developmentally HSCs arise from the AGM, the bone marrow is the
primary site of postnatal hematopoiesis. Defining the precise niche that directly maintains
and regulates HSCs has been challenging due to the difficulty of preserving structural
integrity of the bone during sectioning, combined with the extensive panel of markers
currently required to identify HSCs. Complex biological interactions between prospective
niche cells compound these technical obstacles: genetic perturbation of multiple cell types
in the bone marrow alters HSC number, function, and retention (Calvi et al., 2003; Zhang
et al., 2003), yet an effect on HSCs does not necessarily indicate a direct relationship.
Moreover, the niche is not defined by a single cell type; rather, the niche is the cumulative
environment created by the integration of growth factors, cytokines, oxygen tension, and
other factors presented directly and indirectly to resident HSCs by a range of neighboring
cell types. Recent advances in lineage tracing, high-resolution microscopy, and cell typespecific conditional deletion animal models have contributed significantly to our
understanding of the complex cellular and molecular network responsible for HSC
quiescence, proliferation, retention, and mobilization in vivo.
The bone marrow contains both hematopoietic and non-hematopoietic cells. Boneforming osteoblasts reside at the endosteum, the interface between bone and bone
marrow. Genetic manipulations that increase osteoblast number in mice also increase
HSC number (Calvi et al., 2003; Zhang et al., 2003), and HSCs are observed next to
osteoblasts that express angiopoietin-1, which promotes retention of quiescent HSCs to
the bone marrow (Arai et al., 2004). Although subsequent studies have found these
interactions to be indirect (Kiel et al., 2005; Kiel et al., 2007), these early results
nonetheless provided initial evidence for an endosteal niche.
The bone marrow is highly vascularized, with a particular enrichment of sinusoids
near the endosteum (Nombela-Arrieta et al., 2013). Sinusoids are fenestrated venules that
7

allow passage of cells in and out of circulation. Evidence for a perivascular niche came with
the identification of the SLAM family of markers as a means of visualizing in situ a
population enriched for HSCs (45%) using a simple two-color stain (Kiel et al., 2005). This
made it possible to localize most HSCs adjacent to sinusoids, but less frequently near the
endosteum (Kiel et al., 2007). A possible link between these two potential niches was
suggested by the discovery that most HSCs are in direct contact with cells expressing high
levels of the chemokine CXCL12 (Sugiyama et al., 2006), which is required for HSC
retention to the niche (Broxmeyer et al., 2005) and for engraftment following
transplantation (Peled et al., 1999). Importantly, CXCL12-expressing cells either surround
sinusoidal endothelial cells or are near the endosteum, suggesting a common mechanism
for HSC retention to two niches (Sugiyama et al., 2006).
As the HSC niche remained poorly defined, Morrison and colleagues (Ding et al.,
2012) aimed to identify the cellular source(s) of stem cell factor (SCF), a cytokine required
non-cell-autonomously for HSC maintenance in vivo (Heissig et al., 2002; Czechowicz et
al., 2007). They thus systematically induced deletion of Scf from candidate niche cell types
and found that loss of Scf from hematopoietic, osteoblastic, and Nestin+ mesenchymal
cells did not affect HSC frequency or function. HSCs were depleted from the bone marrow,
however, when Scf was deleted either from endothelial cells or from Lepr+ mesenchymal
cells surrounding sinusoids, and nearly all HSCs disappeared when both cell types lacked
Scf (Ding et al., 2012). Intriguingly, the perivascular mesenchymal cells also expressed
Cxcl12, supporting previous work reporting contact between HSCs and CXCL12producing cells surrounding sinusoidal endothelium (Sugiyama et al., 2006). Subsequent
identification of Hoxb5 as a highly specific marker of long-term HSCs and in situ imaging
of these cells in mouse bone marrow further confirmed the existence of a perivascular HSC
niche (Chen et al., 2016).
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Accumulating evidence suggests that the perivascular niche may not be restricted
solely to sinusoids. Silberstein and colleagues (Nombela-Arrieta et al., 2013) used threedimensional reconstruction of bone sections to perform high-resolution imaging of entire
mouse femurs. They acquired high-throughput information on the positioning of HSCs
(which authors defined as lineage-cKit+CD48-CD41-) throughout the bone marrow,
revealing that most HSCs lie directly adjacent to the bone marrow vasculature. Contrary
to previous work, however, these direct in situ imaging studies found most HSCs localized
near the endosteum (Nombela-Arrieta et al., 2013; Kunisaki et al., 2013). Computer
modeling further revealed that the apparently high association of HSCs with sinusoids that
had been previously described is statistically random when accounting for the density of
the sinusoidal vasculature. Instead, HSCs preferentially associate with endosteal
arterioles, which comprise a smaller volume of the bone marrow. Strikingly, quiescent
HSCs localize to arterioles, while HSC activation or mobilization promotes their
redistribution to sinusoids (Kunisaki et al., 2013). Thus, the arteriolar milieu appears to
represent an additional HSC niche, and this work more broadly supports a model in which
HSC subsets reside in distinct niches (Boulais and Frenette, 2015).
Multiple biological and technical factors may resolve outstanding conflicting
characterizations of the HSC niche. There is an increasing recognition of the functional
heterogeneity of HSCs (Goodell et al., 2015). Complex panels of surface markers are
moreover still required to enrich for putative HSCs. The relationship between various
surface marker combinations and true functional output remains poorly understood, so
seemingly conflicting results may reflect real differences between distinct HSC
populations. HSCs observed at distinct sites within the bone marrow may moreover
represent cells carrying out discrete functions, such as self-renewing versus mobilizing
into circulation. The method of observation moreover has clear effects, as contradictory
9

results have been obtained from transplantation (Xie et al., 2009), induced deletion (Ding
et al., 2012), and in situ visualization (Kunisaki et al., 2013) experiments. The tools
available to characterize the niche have until recently been relatively crude, limited in large
part by the difficulty in analyzing the rare HSC population among large cell numbers in
tissue sections. Such technical limitations likely compound real biological variability.
Despite dense vascularization, the hematopoietic niche is hypoxic (1-5% O2).
Hypoxia limits aerobic respiration and reactive oxygen species (ROS) production and thus
protects stem cells and their progeny from oxidative stress (Suda et al., 2011). The lowest
oxygen tension has been measured in peri-sinusoidal regions of the bone marrow cavity,
while the endosteum is less hypoxic due to a locally higher density of arterioles (Spencer
et al., 2014). While local gradients in oxygen tension therefore exist within the bone
marrow, it remains a suitably hypoxic setting in keeping with existing general models of
the somatic stem cell niche.
An additional factor in interpreting studies defining the HSC niche is that local
oxygen tension changes dramatically following irradiation or chemotherapy due to
damage to the vasculature (Spencer et al., 2014). Conditioning treatments prior to
transplants therefore likely destroy the prospective niches to which HSCs might
preferentially home upon transplantation. Such constraints may explain why HSCs are
more frequently localized to the endosteum in irradiated transplant recipients but
distribute randomly in non-irradiated recipients (Xie et al., 2009). This context-specific
niche selection thus illustrates the need to characterize the niche employing assays that
induce minimal perturbation of the gross tissue architecture.
Significant questions persist about the HSC niche. The increasingly recognized
biological heterogeneity of HSCs (Goodell et al., 2015), combined with remaining technical
limitations to identifying pure HSC populations, likely contribute to some of the
10

inconsistent results reported. Distinct cues and microenvironments are likely required to
support a range of functional outputs. Therefore, distinct niches may exist for HSCs of
different cell cycle status or lineage bias (Ding and Morrison, 2013; Kunisaki et al., 2013).
Additional niche-regulatory signaling from other cell types, including macrophages (Chow
et al., 2011) and Schwann cells (Yamazaki et al., 2011), remains only superficially
characterized. Future development of finer-resolution techniques will help resolve
outstanding conflicting reports and further refine current understanding of the HSC niche.
Finally, most progress in this aspect of HSC biology has been necessarily driven by studies
in mouse. Parallel studies using human cells and humanized mouse models have
contributed to our understanding of the human HSC niche, but significant additional work
is required to identify the unique regulatory network in this setting and translate it to the
clinic.
The regulatory signaling network of HSCs
The role of the niche is to provide the signals to promote HSC quiescence, selfrenewal, mobilization, and differentiation as necessary to support lifelong blood
production. A complex combination of cytokines, adhesion molecules, and other factors
regulates intracellular signaling pathways to direct HSC fate decisions. Thus a thorough
understanding of how these signaling pathways converge into a coherent regulatory
network would significantly support efforts to drive HSC generation de novo or expansion
ex vivo.
Early efforts to drive HSC expansion ex vivo with extrinsic factors focused largely
on the addition of combinations of hematopoietic cytokines, commonly including SCF,
thrombopoietin, and Flt3-ligand. Multiple cytokine cocktails have been reported to
promote expansion of long-term HSCs from human UCB (Conneally et al., 1997; Zhang et
11

al., 2008; Wohrer et al., 2014), but none has yet translated into clinical use. Even currently
reported small molecule-based expansion schemes still rely on the addition of a cocktail
of cytokines (Boitano et al., 2010; Delaney et al., 2010; Chaurasia et al., 2014; Fares et al.,
2014). Such conditions are suboptimal for defining an HSC regulatory network because
cytokines have complex, non-additive effects on HSC survival, proliferation, and selection
of self-renewal versus differentiation (Knapp et al., 2017a). Different cytokine cocktails
correspondingly activate or inhibit distinct signaling pathways (Knapp et al., 2017b).
Cytokine culture is thus a complex system in which to deconstruct HSC fate decisions at
the molecular level, highlighting the need for in-depth characterization of the influence of
individual pathways on HSC fate decisions in a variety of contexts.
In addition to sensitivity to a range of cytokines, HSCs express receptors that can
activate developmental signaling pathways, including Notch (Varnum-Finney et al., 1998),
TGF-β (Yamazaki et al, 2011), Hedgehog (Bhardwaj et al., 2001), and Wnt (Austin et al.,
1997). However, how these pathways integrate into a coherent network that regulates HSC
homeostasis remains unclear.
An overview of canonical Wnt signaling
Extensive evidence indicates a role for canonical Wnt/β-catenin signaling in
development, adult stem cells, and cancer (Clevers, 2006; Wend et al., 2010; Bhavanasi
and Klein, 2016). Wnts are a family of secreted glycoproteins that regulate multiple cell
processes, including cell fate, proliferation, and polarity. In the absence of Wnts, a large
complex scaffolded by Axin facilitates glycogen synthase-3 (GSK-3) phosphorylation of βcatenin and targets it for proteasomal degradation (Kitagawa et al., 1999) (Figure 1.1A).
Upon Wnt binding to its cell surface receptor Frizzled (Fzd), GSK-3 is inhibited, allowing
unphosphorylated β-catenin to accumulate and translocate to the nucleus, where it
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activates the TFs TCF/LEF-1 to drive expression of target genes (Behrens et al., 1996)
(Figure 1.1B). Canonical Wnt target genes include cell proliferation promoters Ccnd1
(which encodes cyclin D1; Tetsu and McCormick, 1999) and Myc (He et al., 1998), as well
as negative feedback regulators of the pathway Axin2 (Jho et al., 2002) and Dkk1 (Bafico
et al., 2001).
Canonical Wnt signaling regulates multiple pathways independently of β-catenin.
The same Wnt/Fzd cascade that stabilizes β-catenin also activates the mammalian target
of rapamycin complex 1 (mTORC1; Inoki et al., 2006), Hippo (Azzolin et al., 2014), and
Wnt stabilization of proteins (Wnt/STOP; Acebron et al., 2014) pathways. These divergent
outputs of Wnt signaling are less well characterized, but there is growing recognition of
their role in normal and malignant physiology (Bhavanasi and Klein, 2016).
mTORC1 is an evolutionarily conserved nutrient sensor that regulates cell
metabolism, growth, and proliferation. GSK-3 enhances the activity of tuberous sclerosis
complex 2 (TSC2), a negative regulator of mTORC1. Thus, Wnt inhibition of GSK-3
relieves GSK-3 inhibition of mTORC1, promoting translation and cell proliferation
independently of β-catenin-mediated transcription (Inoki et al., 2006). Correspondingly,
pharmacologic or genetic inhibition of GSK-3 activates mTORC1 in multiple cell types,
including HSCs (Huang et al., 2009) and ESCs (Mansi Shinde and Peter Klein,
unpublished). This has particularly significant functional consequences for HSCs, as
described below.
Wnt signaling also regulates the Hippo pathway, a conserved regulator of organ
size. Like Wnt/β-catenin signaling, Hippo signaling is regulated by the degradation or
stabilization of transcriptional activators based on the activity of the destruction complex.
Thus upon activation of the Wnt pathway, the Hippo transcriptional activators YAP/TAZ
are released from the destruction complex and translocate to the nucleus to drive
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transcription of Hippo target genes (Azzolin et al., 2014). Aberrant Wnt regulation of
Hippo signaling contributes to tumorigenesis in multiple tissues, including small intestine
(Cai et al., 2010), breast (Lim et al., 2016), and liver (Kim et al., 2017).
Finally, β-catenin-independent Wnt/STOP has been recently identified as an
important mechanism in cell division. Wnt-dependent phosphorylation targets many
GSK-3 substrates for proteasomal degradation (Kim et al., 2009; Xu et al., 2009; Taelman
et al., 2010). In proliferating cells, Wnt signaling peaks during the transcriptionally silent
G2/M phase of the cell cycle (Olmeda et al., 2003). Over 100 candidate proteins have been
identified whose polyubiquitylation depends on GSK-3 and that are stabilized upon
mitotic Wnt signaling, increasing cellular protein content and size in preparation for
division (Acebron et al., 2014). Wnt/STOP is additionally required for mitotic spindle
assembly and faithful chromosome segregation (Stolz et al., 2015).
Canonical Wnt signaling in HSCs
Stem cells are defined by their dual capacity to both self-renew and give rise to
differentiated cells. The balance between these two processes is essential to lifelong stem
cell function, and by extension tissue maintenance and repair. Extensive evidence
demonstrates a key role for Wnt/β-catenin signaling in embryonic, somatic, and cancer
stem cells (Bhavanasi and Klein, 2016). While many reports support a role for Wnt
signaling in the maintenance of HSCs, substantial unresolved contradictory evidence has
accumulated, and the true role of Wnt signaling in HSC maintenance remains
controversial. Given the range of distinct cascades downstream of canonical Wnt
signaling, combined with the variety of approaches employed to investigate its role in HSC
function, the key likely lies in a highly context-dependent role for the pathway.
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Weissman and colleagues (Reya et al., 2003) demonstrated that Wnt/β-catenin
signaling contributes to hematopoiesis with the finding that constitutively activated βcatenin promotes HSC self-renewing proliferation and upregulates expression of HoxB4
and Notch1, both of which had been previously implicated in HSC self-renewal
(Antonchuk et al., 2002; Varnum-Finney et al., 2000). Transplantation of wild-type HSCs
into Sfrp-null hosts (which lack the Wnt antagonist secreted frizzled-related protein 1)
leads to a progressive decrease in HSC numbers (Renstrom et al., 2009), demonstrating a
requirement for niche-mediated regulation of Wnt signaling. Endogenous HSCs moreover
activate a TCF/LEF-1 reporter, indicating that HSCs respond to Wnt signaling in vivo
(Reya et al., 2003). HSC culture with purified Wnt3a (combined with low doses of
cytokines) induces proliferation of cells with multilineage engraftment potential, as
demonstrated by competitive transplant (Willert et al., 2003), suggesting potential clinical
applications for manipulation of Wnt signaling in HSCs. However, reconstitution was
followed only up to six weeks post-transplant, and thus chimerism may have reflected
engraftment by progenitors rather than by true HSCs. Nonetheless, these studies
collectively provided early evidence for the Wnt pathway promoting HSC self-renewal.
Some corresponding studies inhibiting Wnt signaling have yielded consistent
results. Wnt3a-knockout mice die at embryonic day 12.5, but have reduced numbers of
fetal liver HSCs which possess impaired repopulating function in serial transplant (Luis et
al., 2009). Mice with embryonic deletion of Ctnnb1 (which encodes β-catenin) from the
hematopoietic system are viable, but also have HSCs with severely impaired regenerative
capacity (Zhao et al., 2007). Osteoblast overexpression of the secreted Wnt inhibitor Dkk1
moreover results in loss of HSC quiescence and a progressive decline in regenerative
capacity upon transplantation (Fleming et al., 2008), further supporting a role for Wnt
signaling in HSC self-renewal and maintenance.
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However, multiple studies have reported no hematopoietic phenotype upon
deletion of β-catenin, either alone (Cobas et al., 2004) or in combination with deletion of
the functionally related γ-catenin (Jeannet et al., 2008; Koch et al., 2008). Deletion of
Porcn, which encodes an acyltransferase required for Wnt secretion and function (Tanaka
et al., 2000), similarly has no effect on steady-state or regenerative hematopoiesis (Kabiri
et al., 2015). Moreover in contrast to Reya et al. (2003), others observe that expression of
a constitutively active β-catenin leads to a differentiation block in HSCs (Kirstetter et al.,
2006; Scheller et al., 2006). Such findings are difficult to reconcile with a requirement for
Wnt signaling in HSC self-renewal.
Potentially resolving some of the reported inconsistencies, Staal and colleagues
(Luis et al., 2011) have elegantly proposed that Wnt signaling may regulate HSCs in a dosedependent manner. They used combinations of two hypomorphic alleles and conditional
deletion of Apc, a negative regulator of Wnt signaling, to generate varying degrees of
Wnt/β-catenin activation. This demonstrated that low levels of Wnt signaling promote
HSC self-renewal and expansion in vivo, while moderate and high levels of Wnt signaling
promote myeloid and T cell differentiation, respectively. Importantly, the highest level of
Wnt activation leads to total loss of repopulating function in transplant.
A nuanced review of the existing literature further clarifies some of the conflicting
reports. Reya et al. (2003) reported self-renewal in HSCs sorted and transduced with a
stabilized β-catenin construct. Importantly, to induce cell cycle entry for transduction
while limiting differentiation, the authors used HSCs overexpressing the anti-apoptotic
factor Bcl2 (Domen and Weissman, 2000). This study thus employed a tractable but
highly artificial system in which the response to Wnt pathway activation may not
necessarily reflect a biologically relevant response. In contrast, Scheller et al. (2006), who
observed a differentiation block with constitutively active β-catenin, induced expression
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of a stabilized β-catenin on top of endogenous Wnt/β-catenin signaling in adult mice in
vivo. Careful characterization of the extent of Wnt pathway activation in distinct contexts
may thus resolve these conflicting observations and perhaps lend further support to the
dose-dependence model of Wnt regulation of HSC function.
An additional factor likely contributing to the divergent observations reported is
the developmental time point at which the Wnt pathway is manipulated. A self-renewal
defect in HSCs is described when Ctnnb1 is excised prenatally (Zhao et al., 2007), but not
when deletion is induced in adult mice (Cobas et al., 2004; Jeannet et al., 2008; Koch et
al., 2008). Importantly, Wnt reporter activity is observed even in the absence of β-catenin
and γ-catenin (Jeannet et al., 2008), suggesting a potential catenin-independent
mechanism for transduction of Wnt signaling. As β-catenin establishes poised chromatin
architecture at Wnt-responsive regulatory elements in development (Blythe et al., 2010),
it is possible that β-catenin is required during HSC ontogeny to initially define responsive
chromatin architecture, but it is dispensable in adult life provided β-catenin-dependent
epigenetic marks are maintained.
Canonical Wnt signaling is implicated in the regulation of self-renewal and
differentiation of a variety of stem cell populations during homeostasis, tissue
regeneration, and oncogenesis. The extensive literature on the role of Wnt/β-catenin
signaling specifically in HSC function demonstrates the need for highly systematic,
context-specific investigation and nuanced interpretation of new results. Yet despite this
already-detailed characterization of the effects of Wnt pathway manipulation on HSCs,
precisely how the Wnt pathway instructs HSC fate decisions remains relatively poorly
defined. Identifying the downstream effectors that direct distinct HSC programs will yield
important insights into how the Wnt pathway contributes to the signaling network
underlying HSC homeostasis.
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An overview of mTORC1 signaling
As introduced above, mTORC1 is an essential nutrient sensor and regulator of
metabolism that is regulated in part through GSK-3 activation of the TSC1/2 complex.
Cells rely on a complex signaling network that includes mTORC1 to integrate nutrient and
energy availability with the production or digestion of cellular components such as
proteins, lipids, and nucleic acids. mTORC1 regulates transcription of a broad metabolic
gene network (Duvel et al., 2010), but plays an especially central role in regulation of
cellular metabolism at the level of protein synthesis and catalysis. Dysregulation of this
vital process can have disastrous consequences in development, homeostasis, and disease.
In addition to GSK-3, the phosphoinositide 3-kinase (PI3K)/Akt pathway is a
major regulator of mTORC1. Signals such as growth factors, nutrients, and appropriate
oxygen tension recruit PI3K to the plasma membrane, where it phosphorylates PIP 2 to
PIP3 (Vanhaesebroeck and Waterfield, 1999), which itself recruits PDK1 and Akt to the
plasma membrane (Kandel and Hay, 1999). This process is inhibited by phosphatase and
tensin homolog (Pten), which dephosphorylates PIP3 to PIP2 (Vazquez et al., 2006). PDK1
phosphorylates Akt, promoting Akt inhibition of the TSC1/2 complex (Kandel and Hay,
1999). TSC1/2 is one of the primary inhibitors of mTORC1, and thus PI3K/Akt signaling
activates mTORC1 to promote cell survival, growth, and proliferation (Figure 1.2).
mTORC1 promotes cell growth largely through stimulation of translation. The
best-characterized substrates of mTORC1 are thus the 40S ribosomal protein S6 kinases
(S6Ks) and the eukaryotic translation initiation factor 4E-binding proteins (4E-BPs), both
important regulators of translation initiation (Hay and Sonenberg, 2004). mTORC1
phosphorylation of S6K promotes S6K activation of multiple translation initiation factors,
including ribosomal protein S6 (Isotani et al., 1999). mTORC1/S6K signaling also induces
ribosomal gene transcription (Hannan et al., 2003; Xiao and Grove, 2009), further
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promoting ribosomal biogenesis and increasing translational capacity. Under conditions
of low mTORC1 activation, hypophosphorylated 4E-BP competes with eukaryotic
translation initiation factor 4G (eIF4G) to bind and inhibit eukaryotic translation
initiation factor 4E (eIF4E). Activated mTORC1 phosphorylates 4E-BP residues Thr37 and
Thr46. These phosphorylation events are not sufficient to induce 4E-BP dissociation from
eIF4E. However, they are required priming events for subsequent additional
phosphorylation events that ultimately lead to 4E-BP release, allowing eIF4E-eIF4G
interaction and recruitment of the complex to the 5’ cap structure of mRNA (Gingras et
al., 1999; Gingras et al., 2001).
As mTORC1 activity is coupled to cellular energetic availability and demand,
mTORC1 additionally promotes mitochondrial biogenesis and oxidative phosphorylation
activity, through both translation-dependent and -independent mechanisms. mTORC1
inhibition of 4E-BP stimulates mitochondrial biogenesis by selectively promoting
translation of nuclear-encoded mitochondrial protein genes (Morita et al., 2013).
mTORC1 is moreover required for activation of PGC1α, a major transcriptional coactivator
of nuclear-encoded mitochondrial genes (Cunningham et al., 2007; Blattler et al., 2012).
The mTORC1 inhibitor rapamycin correspondingly reduces mitochondrial gene
expression, membrane potential, and oxygen consumption (Paglin et al., 2005;
Cunningham et al., 2007).
In addition to promoting cell growth and metabolism under nutrient-replete
conditions, mTORC1 supports survival during starvation by activating autophagy.
Autophagy also serves as an intracellular quality control mechanism for the turnover of
damaged proteins and organelles. The general process of macroautophagy is the cellular
recycling mechanism whereby autophagic vesicles (autophagosomes) envelop cytoplasmic
proteins and organelles and fuse with the lysosome. Autophagosome contents are thus
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degraded to free amino acids and lipids to support the ongoing biosynthetic needs of the
cell in the absence of exogenous or de novo-produced building blocks (Rabinowitz and
White, 2010). Selective autophagy of mitochondria, ribosomes, and endoplasmic
reticulum (termed mitophagy, ribophagy, and reticulophagy, respectively) has been
described, but how specific cargoes are targeted to the pathway remains poorly
characterized (Cebollero et al., 2012; Joshi and Kundu, 2013). mTORC1 inhibition of
autophagy is twofold: it phosphorylates Ulk1, preventing autophagosome assembly (Jung
et al., 2009), and it phosphorylates the master TF of lysosomal biogenesis TFEB,
sequestering it in the cytosol and preventing transcription of genes required for autophagy
(Roczniak-Ferguson et al., 2012; Settembre et al., 2012).
As translation is considered one of the most energy-consuming processes in the
cell (Hay and Sonenberg, 2004), the rate at which it proceeds must be tightly coupled with
nutrient availability. Control of mitochondrial biogenesis and lipid synthesis is similarly
essential to enacting a stimulus-appropriate metabolic program. Conversely, autophagy
serves in part to generate biosynthetic materials in the absence of sufficient extracellular
supply. Combined, these major regulatory targets of mTORC1 signaling exert reciprocal
control on cellular energy consumption and production.
mTORC1 signaling in HSCs
As described above, HSCs reside in a low-perfusion, reduced-nutrient niche in the
bone marrow. This localization underscores nutrient-sensing and more broadly metabolic
adaptation to this microenvironment as a vital function. HSCs must additionally maintain
a primarily quiescent state to prevent proliferation-induced exhaustion. Consistently,
multiple lines of evidence suggest that mTORC1 signaling is low in HSCs under
homeostatic conditions. A thorough understanding of mTORC1 pathway regulation of
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HSC function and fate decisions will be instrumental in the clinic to induce HSC expansion
without concomitant loss of long-term repopulating function.
Consistent with HSC residence in a hypoxic niche (Parmar et al., 2007; Spencer et
al., 2014), HSCs stably express the oxygen-sensitive TF HIF1α (Takubo et al., 2010). HIF1α
promotes expression of hypoxia-inducible genes, including those related to glycolysis
(Semenza, 2013). HSCs correspondingly exhibit a glycolysis-dependent metabolic profile
(Simsek et al., 2010), as well as low mitochondrial mass and membrane potential (Mantel
et al., 2010) compared to more committed progenitor populations and whole bone
marrow. mTORC1 promotes HIF1α translation (Duvel et al., 2010) and may thus partially
mediate HIF1α regulation of HSC metabolism. Notably, HSCs retain their distinct
metabolic profile for hours after isolation from the bone marrow (Simsek et al., 2010).
This suggests that this reduced metabolism may not be simply an adaptation to the niche,
but rather an intrinsic property of HSCs.
More direct evidence for low mTORC1 signaling in HSCs at homeostasis comes
from loss-of-function studies of multiple negative regulators of mTORC1. Deletion of Pten
(Lee et al., 2010), GSK-3 (Huang et al., 2009), or Tsc1 (Chen et al., 2008; Gan et al., 2008)
leads to HSC proliferation, followed by exhaustion and in some cases leukemia (Lee et al.,
2010; Guezguez et al., 2016). HSCs expressing a constitutively activated Akt similarly
exhibit transient expansion that ultimately leads to impaired engraftment potential and
leukemia (Kharas et al., 2010). Loss of Tsc1 additionally increases mitochondrial
biogenesis and intracellular levels of ROS, consistent with mTORC1 activation. In vivo
administration of an antioxidant, however, preserves HSC number and engraftment
potential, indicating that the TSC/mTORC1 pathway maintains HSC function at least in
part through restricting ROS levels (Chen et al., 2008).
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Although these results collectively establish a clear requirement for low mTORC1
signaling in the maintenance of HSC function, full inactivation of mTORC1 signaling also
causes significant hematopoietic defects. Deletion of Raptor, a regulatory component of
mTORC1 that is required for the complex to function, causes accumulation of immature
progenitors and non-lethal pancytopenia. Although HSC frequency is not affected,
Raptor-knockout cells fail to regenerate the hematopoietic system following transplant or
sub-lethal irradiation (Kalaitzidis et al., 2012). Akt1/2 double-knockout HSCs are
consistently more quiescent and have lower levels of ROS than wild-type and fail to
reconstitute transplant recipients. Pharmacological restoration of ROS levels rescues the
differentiation defect, indicating that some level of Akt activation and ROS is required for
HSC function (Juntilla et al., 2010).
Extensive evidence demonstrates a role for mTORC1 signaling in HSC
maintenance and regenerative capacity. The defects in hematopoiesis observed in
response to either hyperactivation or inhibition of the pathway reveal differential
requirements for it at distinct stages of hematopoiesis. Low mTORC1 signaling appears to
be required for maintenance of quiescent HSCs, in part through promoting a glycolytic
metabolism and restricting mitochondrial content and ROS production in the hypoxic
niche. mTORC1 activation may be necessary, however, to promote the extensive
proliferation that progenitors must undergo to regenerate the hematopoietic system
following injury and to support long-term blood production. The correct level of mTORC1
signaling must therefore be achieved to balance HSC maintenance and proliferation.
Convergence of the GSK-3 and mTORC1 pathways
TSC1/2, a GTPase-activating factor that inhibits mTORC1 (Shaw and Cantley,
2006), is sequentially phosphorylated by AMP-activated protein kinase (AMPK) and GSK22

3 (Inoki et al., 2006). This phosphorylation maintains TSC1/2 suppression of mTORC1
activity, and inhibition of either AMPK or GSK-3 activates mTORC1. Although Wnts
inhibit GSK-3, GSK-3 regulation of mTORC1 is independent of β-catenin (Inoki et al.,
2006).
The convergence of the Wnt and mTORC1 pathways has considerable implications
for stem cells, which must balance signals promoting self-renewal (such as Wnts) and
proliferation (mTORC1) to minimize mutation acquisition and exhaustion. This crosstalk
between the Wnt and mTORC1 pathways has likely contributed to some of the inconsistent
observations reported regarding the effect of Wnt signaling on stem cells, and supports a
nuanced characterization of how both pathways regulate stem cell function. Transient
GSK-3 inhibition and consequent mTORC1 activation may enhance stem cell function in
the short-term. In vivo pharmacological inhibition of GSK-3 in murine HSC transplant
recipients significantly increases donor-derived chimerism. Notably, this treatment
expands the progenitor fraction, but HSC numbers remain constant, and correspondingly
no enhanced reconstitution potential is observed in secondary transplant (Trowbridge et
al., 2006).
In contrast, persistent mTORC1 activation from longer-term loss of GSK-3 leads to
stem cell proliferation followed by exhaustion. Primary recipients of Gsk3-depleted HSCs
show expansion in the HSC fraction of BM. Secondary recipients, however, exhibit
progressive depletion of HSCs (Huang et al., 2009). Importantly, recipient bone marrow
shows both stabilization of β-catenin and increased phosphorylation of S6. These results
are consistent with a role for Wnt/β-catenin signaling in maintenance of the HSC pool,
but also demonstrate that mTORC1 is activated in Gsk3-depleted cells. Administration of
rapamycin to transplant recipients preserves Gsk3-depleted HSCs, confirming that this
exhaustion is mTORC1-dependent. This two-step phenotype has also been demonstrated
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in epidermal stem cells (Castilho et al., 2009), suggesting that the mechanism may exist
more broadly in additional stem cell populations.
Proposed model for GSK-3 and mTORC1 regulation of HSC maintenance
These results indicate a dual role for GSK-3 in HSC homeostasis: GSK-3 inhibition
of Wnt/β-catenin inhibits self-renewal, while GSK-3 inhibition of mTORC1 inhibits
lineage commitment. Inhibition of GSK-3 alone is therefore predicted to activate both
pathways, yielding the observed initial expansion and ultimate depletion of HSCs. The
Klein laboratory has proposed a model in which simultaneous inhibition of GSK-3 and
mTORC1 may inhibit lineage commitment while promoting self-renewal (Figure 1.3). If
this is the case, then this model deconstructs the aggregate network that maintains HSCs
down to the minimal signals required to sustain HSC function. This would be a significant
advance, as the complex and incompletely defined niche in which HSCs reside in the bone
marrow has constrained efforts to define this network in vivo. The development of a model
system that could maintain HSCs ex vivo under defined conditions would allow further
identification of specific targets that mediate HSC maintenance. More precise definition
of the signaling network that maintains HSCs will moreover provide rationale for ongoing
efforts to expand HSCs ex vivo for both research and clinical applications.
Conclusion
The clinical potential of HSCs has been recognized for over a half century, yet
substantial barriers remain before this full potential is achieved. One such barrier has been
an incomplete characterization of the signaling network that generates, maintains, and
expands HSCs throughout life. The Wnt/β-catenin and mTORC1 pathways are central
components of this network, although their functional consequences are complex and
context-specific. More precise identification of the targets of these pathways in the
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regulation of HSC function will yield important insights toward expanding their successful
use in the clinic.
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Figure 1.1: The Wnt/β-catenin pathway. (A) In the absence of Wnts, Axin, CK-1a,
GSK-3, and APC form the β-catenin destruction complex. Sequential phosphorylation of
β-catenin by CK-1a and GSK-3 in the destruction complex targets β-catenin for
proteasomal degradation. (B) On Wnt binding to the Fzd/LRP co-receptors, Axin is
recruited to LRP and the complex is inactivated. Unphosphorylated, stabilized β-catenin
accumulates and translocates to the nucleus, where it activates TFs TCF/LEF to promote
transcription of Wnt target genes.
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Figure 1.2: The PI3K/Akt/mTORC1 pathway. Signals including growth factors and
nutrients recruit PI3K to the plasma membrane. PI3K phosphorylates PIP2 to PIP3, which
recruits PDK1 and Akt to the plasma membrane. Pten inhibits this process by
dephosphorylating PIP3 to PIP2. PDK1 activation of Akt promotes Akt inhibition of
TSC1/2, relieving TSC1/2 inhibition of mTORC1 signaling. mTORC1 promotes cell growth
and metabolism through a variety of effector pathways.
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Figure 1.3: Proposed model for GSK-3 and mTORC1 regulation of HSCs. GSK3 regulates two antagonistic pathways in HSCs. GSK-3 inhibition of Wnt/β-catenin
signaling inhibits self-renewal, while GSK-3 inhibition of mTORC1 inhibits lineage
commitment. Inhibition of GSK-3 activates both pathways. Simultaneous inhibition of
GSK-3 and mTORC1 may therefore block HSC lineage commitment while promoting selfrenewal.
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CHAPTER 2: HSC MAINTENANCE VIA GSK-3 AND MTORC1 INHIBITION
The data presented in this chapter were published in Nature Medicine (Huang et al.,
2012).
Introduction
HSCs support lifelong maintenance of the blood at homeostasis and following
injury. They are an important model system in the study of stem cells and widely used in
the clinic to treat hematopoietic malignancies and bone marrow failure (Purton and
Scadden, 2007). Extensive effort has been invested in promoting HSC expansion ex vivo,
both to facilitate further characterization in basic research and to improve clinical
outcomes and broaden potential therapeutic applications. However, HSCs in vivo rely on
a panoply of signals from their microenvironment to sustain their function. An incomplete
understanding of the signaling network that maintains HSCs has significantly constrained
the ability to maintain or expand HSCs beyond the niche (Lymperi et al., 2010).
HSCs reside in a hypoxic, low-perfusion niche (Parmar et al., 2007; Spencer et al.,
2014), emphasizing the importance of nutrient-sensing in HSC homeostasis. The
evolutionarily conserved nutrient sensor mTORC1 integrates diverse signals including
nutrient availability, mitogenic stimuli, and oxygen tension, and the mTORC1 signaling
pathway is correspondingly vital to HSC maintenance. Loss of function of multiple
negative regulators of mTORC1, including Pten (Lee et al., 2010), Gsk3 (Huang et al.,
2009), and Tsc1 (Chen et al., 2008), leads to HSC proliferative exhaustion and in some
instances leukemia (Lee et al., 2010; Guezguez et al., 2016). These observations identify
low mTORC1 signaling as an essential component of the network that maintains HSCs.
Extensive literature additionally implicates the Wnt/β-catenin pathway in the
regulation of HSCs, particularly in promoting self-renewal (Reya et al., 2003; Willert et
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al., 2003), although this role remains controversial. Embryonic deletion of Wnt3a (Luis et
al., 2009) or of Ctnnb1 (which encodes β-catenin) (Zhao et al., 2007) impairs HSC selfrenewal. However, deletion of Ctnnb1 in adult mice produces no hematopoietic phenotype
(Cobas et al., 2004; Jeannet et al., 2008; Koch et al., 2008), and expression of a
constitutively active β-catenin causes a differentiation block (Kirstetter et al., 2006;
Scheller et al., 2006). The effect of Wnt/β-catenin signaling on HSCs is thus contextdependent.
Interpretation of the effect of Wnt signaling on HSCs is complicated in part by
crosstalk with other pathways. For example, Wnt signaling activates mTORC1
independently of β-catenin (Inoki et al., 2006). The dual activation of β-catenin and
mTORC1 by Wnts may therefore explain why GSK-3 inhibition leads to transient
expansion (Trowbridge et al., 2006) followed by mTORC1-dependent depletion of HSCs
(Huang et al., 2009). The Klein laboratory therefore tested the hypothesis that activating
Wnt/β-catenin signaling and mimicking restricted nutrient availability would together
promote the self-renewal pathway while blocking the lineage commitment pathway. In
support of this model, we found that simultaneous inhibition of GSK-3 and mTORC1
supports the maintenance of long-term HSC function ex vivo in the absence of serum or
exogenous cytokines (Huang et al., 2012). This work identifies a signaling network that
maintains HSCs and describes the first method to maintain HSCs beyond the niche under
completely defined conditions. This method therefore represents a valuable tool to
interrogate the signals that maintain HSC function, as well as a potential platform to
screen for compounds that induce expansion ex vivo.
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GSK-3 and mTORC1 inhibition maintains HSC multilineage potential
Previous work from the Klein laboratory (Huang et al., 2009) reported a two-step
phenotype in bone marrow depleted of Gsk3a/b: primary recipients of these cells exhibit
enhanced donor-derived chimerism compared to wild-type, but secondary and tertiary
recipients experience a progressive decline in HSC function. Donor-derived cells display
increased S6 phosphorylation, indicating mTORC1 activation in the absence of GSK-3.
Administration of the mTORC1 inhibitor rapamycin to secondary transplant recipients
preserves HSC function, demonstrating that the progressive hematopoietic failure is
mTORC1-dependent. mTORC1 inhibition therefore sustains HSC function in the context
of Wnt pathway activation in vivo (Huang et al., 2009).
As these studies were performed in vivo, we could not rule out the possibility that
additional factors from the microenvironment may have contributed to HSC maintenance
in the context of dual GSK-3 and mTORC1 inhibition. To address this question, we tested
whether combined inhibition of GSK-3 and mTORC1 was sufficient to maintain HSCs ex
vivo under completely defined conditions. We cultured cKit+ bone marrow cells, which are
enriched for hematopoietic stem and progenitor cells (HSPCs), for 7 days in serum-free,
cytokine-free medium supplemented only with the GSK-3 inhibitor CHIR99021 and
rapamycin (CR), followed by functional assessment (Figure 2.1A). Induction of the Wnt
target gene Axin2 in CHIR99021-treated cKit+ cells (with or without rapamycin)
confirmed activation of Wnt/β-catenin signaling under these conditions (Figure 2.1B).
As a preliminary test of hematopoietic potential after cytokine-free culture, we
seeded cKit+ cells at three concentrations onto stromal cells that support hematopoietic
differentiation (Holmes and Zuniga-Pflucker, 2009). Each concentration was co-cultured
in triplicate wells. After two serial passages over 21 days in this stromal co-culture, we
performed flow cytometry for hematopoietic lineage markers. This analysis revealed that
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CR-cultured HSPCs retained multilineage potential, while vehicle-cultured cells did not
(Figure 2.1C,D).
The cKit+ fraction of the bone marrow is a highly heterogeneous population, so we
repeated these experiments in Lin-Sca1+cKit+ (LSK) cells, which are more highly enriched
for HSPCs. We cultured LSK cells for 7 days in CR without serum or cytokines, and then
transferred the cells to stromal co-culture for 21 days. Flow cytometric analysis again
demonstrated both myeloid and lymphoid potential of CR-cultured HSPCs, which was
absent from vehicle-cultured cells (Figure 2.1E).
Conclusion
These results provided initial proof of principle that GSK-3 and mTORC1
inhibition is sufficient to sustain at least some hematopoietic function ex vivo. CRcultured HSPCs gave rise to both myeloid and lymphoid cells, indicating multilineage
potential. However, stromal co-culture may allow non-physiological lineage commitment
of hematopoietic cells (Richie Ehrlich et al., 2011) and is not a definitive test of HSC
function. In addition to multilineage differentiation, HSC function must also be
demonstrated by the capacity to self-renew. As the current gold standard to confirm these
dual properties is bone marrow transplantation, the first author subsequently performed
serial transplantation of cultured cKit+ cells into irradiated recipients. CR-cultured HSPCs
gave rise to multilineage chimerism and engrafted primary, secondary, and tertiary
recipients, demonstrating robust self-renewal capacity (Huang et al., 2012). The first
author additionally identified β-catenin as an essential mediator of this signaling network,
as Ctnnb1-knockout cKit+ cells cultured in CR failed to generate hematopoietic cells in
stromal co-culture. Importantly, human UCB CD34+ cells cultured in CR also gave rise to
multilineage chimerism in serial transplant, indicating that this signaling network
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supports both murine and human HSC maintenance. Taken together, this work shows that
the combination of Wnt pathway activation and mTORC1 inhibition supports the
maintenance of long-term, self-renewing HSCs in defined, cytokine-free conditions.
These findings identify a minimal set of signals required to maintain HSC function
beyond the niche. The defined conditions described here thus establish a novel system in
which to interrogate the signals that mediate HSC maintenance. Hematopoietic cytokines
seem to be essential for the survival of HSPCs beyond the niche, but they likely promote
proliferation at the expense of self-renewal (Hofmeister et al., 2007; Chou et al., 2010).
Combinations of cytokines additionally interact in often synergistic (non-additive) ways
(Ahsberg et al., 2010; Knapp et al., 2017b), confounding interpretations of molecular and
functional responses to cytokine treatment. The finding here that GSK-3 and mTORC1
inhibition maintains HSCs in the absence of cytokines provides a novel platform that
allows the culture of HSCs under defined conditions, substantially simplifying in-depth
characterization of the signaling network that regulates HSC function.
In summary, we reported that simultaneous Wnt activation and suppressed
nutrient-sensing by mTORC1 is sufficient to maintain HSC function in the absence of
serum or exogenous cytokines. This model culture system identifies a minimal signaling
network required to maintain HSCs and lays the groundwork for testing additional
compounds that, in combination with GSK-3 and mTORC1 inhibition, might promote HSC
expansion while preserving self-renewal. A thorough understanding of the mechanism of
GSK-3/mTORC1-inhibition-mediated maintenance will yield substantive insight toward
additional pathways to target in the search for conditions that will promote such
expansion. Although Wnt/β-catenin signaling is required for this maintenance, defining
additional downstream effectors by which GSK-3 and mTORC1 inhibition maintains HSC
function is an important goal of follow-up work.
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Figure 2.1: Multilineage potential of HSPCs cultured with GSK-3 and mTORC1
inhibitors.
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Figure 2.1: Multilineage potential of HSPCs cultured with GSK-3 and mTORC1
inhibitors. (A) Experimental design. Mouse cKit+ or LSK cells were cultured in cytokinefree medium with vehicle or CR for 7 days and then either plated on OP9 or OP9-Dl1
stromal cells or transplanted into lethally irradiated mice. Flow cytometry was performed
after 3 weeks of co-culture or 4 months after transplantation. Hematopoietic cells were
distinguished from OP9 cells (which are GFP+) by gating on the CD45.2+GFP- population.
(B) Mouse cKit+ cells were harvested and treated for 12 hours with DMSO, CHIR99021, or
CR. Expression of the Wnt target gene Axin2 was measured by RT-PCR. (C) Effect of CR
on cKit+ cells after 7 days in culture. After 7 days of cytokine-free culture, cKit+ cells were
serially diluted and plated on OP9 stromal cells. After 3 weeks of co-culture, flow
cytometry for hematopoietic cells was performed, and number of positive wells out of total
wells was counted. Wells with >1% myeloid lineage out of the total number of viable cells
were scored as positive. (D,E) Representative flow cytometry data (left panels) and
quantification of myeloid, B, and T lineages (right panels) from cKit+ (D) or LSK (E) cells
that were cultured for 7 days, plated on OP9 or OP9-DL1 cells, and assessed for myeloid
(OP9), B, and T (OP9-Dl1) lineage markers. Cultured hematopoietic cells were plated on
stromal cells in triplicate wells. Histograms represent the mean value from three wells
(error bars, S.D.). (The overall experiment was performed twice.)
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CHAPTER 3: TRANSCRIPTION PROFILING IN HSC MAINTENANCE
Introduction
HSCs rely on a range of cues from the niche to sustain their function and to instruct
cell fate decisions. Parsing out individual contributions of these stimuli in vivo to define
the signaling network that maintains HSCs has therefore presented a major challenge to
the study of HSC biology, moreover compounded by interactions between these stimuli.
An incomplete understanding of these cues has furthermore precluded development of
controlled conditions ex vivo to characterize these pathways. A deeper characterization of
this network will inform the investigation of signals regulating HSC homeostasis both in
vivo and in the context of ex vivo expansion for research and clinical applications.
We showed previously that simultaneous inhibition of GSK-3 and mTORC1
maintains HSC function ex vivo without the need for serum or exogenous cytokines
(Huang et al., 2012). This is the first time HSCs have been maintained ex vivo in the
absence of cytokines. Cytokines historically have been used to culture HSCs, but at the
expense of concomitant lineage commitment (Hofmeister et al., 2007; Chou et al., 2010).
The novel culture conditions we described therefore represent a defined system in which
to interrogate a signaling network that maintains HSCs. Although β-catenin is required
for this maintenance, the mechanism by which GSK-3 and mTORC1 inhibition maintains
HSCs remains otherwise unclear. I therefore proposed transcriptional profiling of HSCs
preserved under these conditions as a means to characterize this maintenance program in
a defined setting, isolated from complex and interacting inputs from the niche.
Specifically, I aimed to compare the gene expression profiles of freshly isolated HSCs and
of HSCs cultured with vehicle, GSK-3 inhibitor CHIR99021, mTORC1 inhibitor
rapamycin, or both (CR). I predicted that CR-maintained HSCs would have a
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transcriptional profile that was distinct from vehicle- or single-treated cells, and that
components of this profile would be required for the maintenance of HSC function.
Reduced RNA content in cultured HSCs
Quiescent (G0) cells can be identified in part by a lower RNA content compared to
actively cycling cells (Holyoake et al., 1999; Challen et al., 2009). HSCs correspondingly
contain less total RNA than progenitors (Signer et al., 2014). Quiescent murine HSCs
(Huttmann et al., 2001) and satellite cells of the skeletal muscle (Fukada et al., 2007)
additionally contain less RNA than their activated counterparts, as measured by staining
for the RNA dye pyronin Y. Aged human HSCs, which are less quiescent than young HSCs,
are also correspondingly more frequently in the pyronin Y-high fraction than young
human HSCs (Pang et al., 2011). Consistent with these reports, I observed that freshly
isolated HSCs contain less total RNA per cell than hematopoietic progenitor cells (LinSca1-cKit+ [LK]; HPCs), as measured by nanofluidic electrophoresis (Figure 3.1A). I
additionally discovered that RNA was undetectable in cells after 3 days of culture (as
described in greater detail in Chapter 4), regardless of treatment. Importantly, cellular
RNA was undetectable despite recovery of up to 70% of an mRNA spiked into each sample
at the time of cell lysis (Figure 3.1B), indicating that RNA was stable during isolation.
CR-cultured cells were moreover viable, as they excluded Trypan blue and engrafted in
transplant recipients (as detailed in Chapter 4). I therefore conclude that the lack of RNA
recovery from cultured HSCs does not represent a technical limitation, but rather an
intriguing biological process associated with hematopoietic cells in cytokine-free culture.
RNA-seq on HSCs maintained ex vivo
To overcome the limitation of vanishingly small quantities of RNA in cultured
HSCs, I adapted an aRNA amplification protocol designed to permit transcriptome
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analysis of single cells (Morris et al., 2011). Briefly, polyadenylated RNAs serve as the
template to generate double-stranded cDNA into which a T7 RNA polymerase promoter is
incorporated. An in vitro transcription reaction with T7 RNA polymerase then produces
antisense transcripts (aRNA). This process is performed for two to three rounds, with
slight technical modifications following the first round to use the aRNA as template. In
theory, the method produces linear amplification of polyadenylated transcripts,
preserving the relative abundance of components of the transcriptome and generating
sufficient material for RNA-seq analysis. With a potential solution to the limited quantity
of RNA in cultured HSCs, I performed gene expression profiling in these cells.
I sorted HSCs for RNA isolation either immediately after sorting or following 3
days in culture under defined conditions as described (Huang et al., 2012). Cultured cells
were treated with vehicle, CHIR99021, rapamycin, or both. Following RNA isolation, all
samples underwent three rounds of aRNA amplification, and aRNA was provided to the
Perelman School of Medicine Next-Generation Sequencing Core for library preparation
and RNA-seq. I completed five biological replicates of this analysis.
As an initial assessment of the gene expression profiles, I assessed principal
component analysis (PCA). Although most samples clustered closely together, PCA
showed several experimental outliers (Figure 3.2A). I excluded those outliers from
further analyses. PCA on the remaining samples revealed tight clustering of uncultured
HSCs (Figure 3.2B), demonstrating that the starting populations sorted were similar
across experimental replicates. Cultured samples formed a second, looser cluster, but they
did not generally group by drug treatment (Figure 3.2B). This suggested that further
analysis may not reveal substantial differences in gene expression between CR- and
control-cultured HSCs.
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I nonetheless analyzed transcription profiles for genes that fulfilled two criteria: 1)
expression level was <1.2-fold different in CR-cultured HSCs compared to uncultured
HSCs, and 2) expression level was ≥1.5-fold different in CR-cultured HSCs compared to
control-cultured HSCs (with a false discovery rate <25%). One hundred forty-three genes
fulfilled these criteria. Based on their reported functions, about half of these genes grouped
into recurrent categories (Figure 3.3A). Notably, this analysis identified 18 genes related
to the ribosome, including 12 ribosomal protein genes. A more systems-level analysis of
the full 143-gene list using Ingenuity Pathway Analysis (IPA) suggested enhanced eIF2 or
Myc signaling in CR-cultured HSCs could be responsible for the observed expression
patterns, primarily due to the presence of the ribosomal genes.
I next attempted to validate some of these RNA-seq results by RT-PCR. I
performed RT-PCR for four of the ribosomal protein genes that fulfilled the initial criteria
for defining genes of interest. Although neither Myc nor Mycn was on this list, I assessed
their expression levels as well, based on the suggestion from the IPA that Myc signaling
may be uniquely enhanced in CR-cultured HSCs compared to controls. In the RNA-seq,
Myc expression decreased over 10-fold in all cultured cells compared to uncultured
(Figure 3.3B, top panel). Mycn expression was also substantively lower in all cultured
cells compared to uncultured, although the magnitude of reduction varied. Two biological
replicates of RT-PCR reproduced the reduction in Myc expression in cultured cells, but
were less consistent in Mycn expression (Figure 3.3B, top panel). Ribosomal protein
gene expression by RT-PCR varied even more from the RNA-seq and revealed a consistent,
substantial decrease in detected expression in cultured versus uncultured cells (Figure
3.3B, middle and bottom panels). This result was particularly problematic given that
I selected these genes based on their similar expression levels in uncultured and CR-
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cultured cells according to the RNA-seq. Taken together, I conclude that the RNA-seq
dataset may be unreliable.
Testing aRNA amplification method
The extensive RNA processing necessary to generate sufficient material for RNAseq, combined with the inability to confirm RNA-seq results by RT-PCR, led me to test
whether any observed differences in gene expression represented true biological
differences, or if they might simply be technical artifacts of the amplification technique.
In particular, if there were any measurable bias in amplification (such as for short versus
long transcripts), then the multiple rounds of amplification required would magnify this
bias. I therefore did a serial dilution of total RNA isolated from 650 HPCs, followed by
aRNA amplification. If amplification was linear, then I would predict that diluting the
input RNA would yield a stepwise decrease in the total amount of RNA at the end of the
amplification process. However, more dilute samples yielded only modest decreases in
final RNA yield (Figure 3.4A). It is noteworthy that the technique was originally
optimized for amplification of RNA from single cells (Morris et al., 2011), while the
linearity test described here used RNA from hundreds of cells. It is therefore possible that
I failed to obtain a reduction in yield at the higher input RNA concentrations (undiluted,
1:5, 1:20) due to saturation of the system. However, the more dilute samples (1:100, 1:500)
also failed to yield a magnitude of decrease in aRNA generation that reflects the amount
of input material. I therefore conclude that aRNA amplification is only approximately
linear at best.
I next tested whether individual transcripts were uniformly amplified across
samples subjected to this method. I used a fixed amount of aRNA from each of the serially
diluted RNA samples described above for cDNA synthesis and performed RT-PCR for five
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genes. All samples originated from a single RNA sample, ensuring that the relative
abundance of each transcript was equivalent prior to amplification. If amplification was
uniform, then these relative abundances would be preserved following amplification.
Instead, I observed a distinct effect of initial input RNA dilution on the amount of each
transcript detected by RT-PCR (Figure 3.4B), indicating that the technique does not
reliably preserve relative transcript abundance. Based on the observations that the aRNA
amplification method amplified RNA in a manner that was neither linear nor uniform, I
conclude that the technique was not an appropriate solution to resolve the significant
reduction in cellular RNA content observed in cultured HSCs and thereby perform
transcriptomic analysis of these cells.
Normalizing expression data from samples with distinct amounts of RNA
In addition to the exceptionally small amount of RNA in cultured cells, the
differing amounts of total RNA in uncultured and cultured cells (Figure 3.1) presented a
further challenge in performing expression profiling on HSCs maintained ex vivo.
Standard practice in global gene expression analysis introduces equivalent amounts of
RNA from samples to be compared and normalizes the total signal (Mortazavi et al.,
2008). This approach relies on the assumption that the cellular sources being analyzed
produce similar amounts of RNA. However, two groups have reported that cells expressing
high levels of the transcription factor c-Myc are larger and contain two to three times more
total RNA than their wild-type counterparts (Lin et al., 2012; Nie et al., 2012). Rather than
defining specific c-Myc target genes, this work therefore identifies c-Myc as an amplifier
of the global transcriptional program that is already active in cells. More broadly, however,
these findings indicate that the conventional normalization approach is not appropriate
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for samples that contain different amounts of RNA, as this can both distort apparent
relative expression levels across samples and mask true changes in global transcription.
To resolve this limitation, Young and colleagues (Loven et al., 2012) have proposed
spiking in a fixed amount of standard RNAs per cell in samples to be subjected to global
transcription profiling, permitting normalization to cell number per sample and thus
detection of changes in gene expression at the level both of individual genes and of the full
transcriptome. Although Loven et al. (2012) spike in the RNA standards following cellular
RNA isolation, the method can additionally control for variability in RNA isolation
efficiency across samples if the standards are spiked in at the time of cell lysis. In light of
these factors, spiking in RNA standards is an attractive strategy to overcome some of the
unique challenges presented by my efforts to perform transcription profiling in uncultured
and cultured HSCs. This approach will additionally prove important as future gene
expression analyses factor in differences in total RNA content under more physiological
settings, such as in quiescence (Bulut-Karslioglu et al., 2016), differentiation (Signer et al.,
2016), and cancer (Percharde et al., 2017).
Proposed method for transcription profiling in HSCs maintained ex vivo
Based on my observations in early attempts to perform gene expression profiling
in HSPCs, I present here a detailed workflow describing how such analysis could be
completed to define the transcriptional profile of HSCs maintained ex vivo. The
techniques outlined below account for the obstacles presented by the differing and low
RNA quantities encountered in my samples of interest. (The RNA content in cultured cells
is so low that simply starting the experiment with more cells is not sufficient to address
the obstacles encountered, due to the number of mice that would be required.) This

42

analysis would allow identification of a gene expression signature in cultured HSCs that is
specific to cells that retain self-renewal and multilineage repopulating functions.
Due to the panel of multiple markers currently required to isolate high-purity
HSCs, flow cytometric sorting of cells is necessary to perform any analysis on HSCs.
However, the shear stress of flow cytometric sorting has been reported to modestly but
measurably reduce post-sort viability in a variety of cell types (Mollet et al., 2007; Zaitoun
et al., 2010). The mechanical stress of sorting additionally influences gene expression
(Avvisato et al., 2007; Beliakova-Bethell et al., 2014). Although these factors apply to
sorted cells in all samples and the magnitude of these changes is relatively small, they
should be minimized where possible. All of the experiments described in this dissertation
were performed using HSPCs sorted on a FACSARIA II (BD Biosciences). However, for
future experiments involving highly sensitive analyses, such as gene expression profiling,
sorting cells on an INFLUX may be a more appropriate choice. Compared to standard
sorters such as the FACSARIA, the INFLUX combines a distinct nozzle shape and low
sheath pressure to accelerate cells more smoothly and under lower shear stress following
stream interception with the lasers, improving cell viability (BD Biosciences) and
potentially minimizing changes in gene expression induced by the mechanical force of
sorting.
Following HSC isolation, I initially cultured cells in vehicle, CHIR99021,
rapamycin, or both inhibitors for 3 days before RNA extraction for gene expression
profiling. In choosing this length of culture, I aimed for the shortest period that would
yield a transcriptional profile in CR-maintained HSCs that was distinct from that of HSCs
cultured in only one or neither inhibitor. In particular, I predicted that rapamycindependent transcriptional changes would take time to accumulate, as mTORC1 influences
transcription in part through regulating translation and activation of TFs (Laplante and
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Sabatini et al., 2013; Showkat et al., 2014). However, Manning and colleagues treated
Tsc1- or Tsc2-null mouse embryonic fibroblasts with rapamycin and observed mTORC1dependent changes in transcription in as little as 6 hours (Duvel et al., 2010). The dramatic
reduction in total RNA content observed in cultured cells by day 3 (Figure 3.1B)
additionally suggests that a shorter culture period (perhaps 1 day) would be sufficient to
identify a unique transcriptional profile in maintained HSCs. This observation moreover
reveals a robust effect of culture itself, independent of maintenance of function. A shorter
culture period would therefore minimize artifacts of the culture while likely still yielding
informative differences in gene expression.
As introduced above, the incorporation of spiked-in RNA standards (Loven et al.,
2012) would be essential to appropriate analysis of the gene expression profile of cultured
HSCs.

Cultured cells contain an undetectably low amount of RNA (Figure 3.1B),

precluding any controls at the level of inputting a constant quantity of RNA per sample to
the library preparation and RNA-seq workflow. RNA standards added to lysates on a percell basis at the time of cellular RNA isolation would therefore serve as an important
control at normalization. The ability to normalize reads to RNA per cell would additionally
allow accurate comparison of cellular transcript abundance between uncultured HSCs and
HSCs maintained ex vivo, which contain different amounts of RNA. This is a robust
phenotype that would be masked by conventional normalization methods. Notably,
spiked-in RNA standards compose only ~1-5% of total reads, so conventional
normalization methods can still be applied to analyze cellular transcripts. This flexibility
of the platform therefore permits detection both of global shifts in transcription (by
normalizing to spiked-in RNAs as a surrogate for cell number) and of extreme outlier
genes (by conventional normalization to read depth) (Percharde et al., 2017).
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Finally, gene expression profiling of cultured HSCs would require RNA
amplification to obtain a usable quantity of RNA for library preparation and transcriptome
analysis. Although the aRNA amplification method was not reliable in my hands (Figure
3.4), the SMARTer Pico PCR cDNA Synthesis kit (Clontech) may be a better tool. The
method relies on SMART (Switching Mechanism at 5’ end of RNA Template) technology
with a proprietary reverse transcriptase that generates double-stranded cDNA from
picogram quantities of total RNA. Briefly, oligo(dT) with an added 5’ sequence primes
reverse transcription of polyadenylated transcripts. Upon reaching the 5’ end of the
template RNA, the reverse transcriptase adds several nucleotides to the 3’ end of each
cDNA. A distinct SMARTer oligo then base-pairs to the extended tail and primes the
second-strand cDNA synthesis. Standard reverse transcription is prone to interruption by
template RNA secondary structure. As cDNAs prematurely terminated in the SMARTer
protocol fail to incorporate the 3’ SMARTer oligonucleotide, they are not amplified by
subsequent PCR. This approach therefore enriches for generation and amplification of
full-length cDNAs. The method is moreover compatible with the addition of spiked-in
transcripts, as commercially available RNA standards (such as from the External RNA
Controls Consortium) are polyadenylated. Notably, the SMARTer kit manufacturer
recommends a minimum starting amount of 20 pg/μl (Clontech), but success has been
described with as little as 10 pg total RNA (Igor Antoshechkin, personal communication).
This technology is therefore ideally suited for the amplification of RNA isolated from
cultured HSCs.
Together, the workflow described here presents an informed strategy broadly
applicable to gene expression profiling in cells with differing and/or limiting quantities of
RNA. This approach will therefore be especially valuable to define a transcriptional
program that is specific to HSCs maintained under the Klein laboratory’s defined ex vivo
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conditions. Further characterization of this profile may identify both novel regulators of
HSC maintenance and rational targets to promote their expansion while preserving
function to facilitate molecular characterization and clinical applications of HSCs.
Conclusion
The HSC niche instructs HSCs with diverse signals. A long-standing challenge in
the study of HSCs has therefore been characterizing pathways that regulate their function
and fate. The Klein laboratory’s conditions to maintain HSCs ex vivo under defined
conditions (Huang et al., 2012) represent a valuable tool to achieve this goal.
Transcriptional profiling of these HSCs, and comparison to uncultured HSCs and to HSCs
cultured under conditions that do not maintain stem cell function, could yield significant
insight into the signaling network that maintains HSCs.
Given how drastically different the HSC niche is from the culture conditions we
have reported to maintain HSCs ex vivo, it was somewhat unsurprising that the gene
expression profile of these cells bore limited overlap with that of uncultured HSCs (Figure
3.2B). This prediction was supported by the dramatic decrease in RNA content observed
in cultured compared to uncultured HSCs (Figure 3.1B). The comparison may
nonetheless be informative for two reasons. First, minimal overlap of only a handful of
genes between these two populations would significantly filter down the total
transcriptional program to just those genes that fundamentally drive retention of longterm HSC function. Second, the comparison of uncultured and cultured HSCs will help
define how HSCs maintain their function while adapting to an environment beyond the
niche, providing valuable insight as researchers attempt to expand HSCs ex vivo to
facilitate basic and translational research.
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Deep sequencing could reveal a more nuanced level of transcriptional regulation
in HSC maintenance by additionally permitting analysis of alternative splicing events.
Gazit and colleagues recently described comprehensive mapping of splicing in mouse
HSCs, uncovering alternative splicing throughout the transcriptome (Goldstein et al.,
2017). They furthermore observed some enrichment for multiple isoforms of genes
preferentially expressed in HSCs, such as Hlf, HoxA9, and Prdm16, and some of these
isoforms exhibited distinct levels of activity. GSK-3 has been identified as a regulator of
alternative splicing (Heyd and Lynch, 2010; Mansi Shinde and Peter Klein, unpublished),
suggesting the intriguing possibility that in addition to β-catenin-dependent transcription
(Huang et al., 2012), altered RNA splicing could be a pathway through which GSK-3
inhibition contributes to HSC maintenance ex vivo.
Although all of the work presented in this dissertation was performed in mouse
HSPCs, the ultimate goal is improved characterization and clinical application of human
HSCs. The experimental workflow presented in this chapter is readily applicable to human
HSCs. The identification of markers such as CD49f (Notta et al., 2011) has enabled
isolation of highly purified human HSCs, a technical advance that will promote a more
refined definition of the human HSC regulatory network.
Finally, my attempts to perform transcription profiling in cultured HSCs revealed
a dramatic decrease in total RNA content, an unexpected but highly robust response of
HSCs to serum- and cytokine-free culture. This phenotype was accompanied by a
remarkable decrease in cell size (as described in Chapter 4). The reduction in RNA content
is consistent with a quiescent state, as has been recently reported in mouse blastocysts
pharmacologically diapaused with an mTORC1 inhibitor (Bulut-Karslioglu et al., 2016).
Notably, however, I observed this in all cultured cells, regardless of retention of HSC
function. It may therefore not be a component of the mechanism of HSC maintenance ex
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vivo, but rather an artifact of the culture itself. The limited quantity of RNA in all cultured
cells highlights the possibility that HSCs maintained ex vivo under these conditions may
exhibit only modest differences in expression levels of specific genes compared to controlcultured HSCs. By extension, HSC maintenance may be mediated post-transcriptionally.
For example, β-catenin recruits chromatin remodelers (Blythe et al., 2010) as well as
promotes target gene transcription, and mTORC1 is a known regulator of translation.
Chromatin immunoprecipitation for assessment of histone modifications is now possible
starting with as few as 10,000 cells (Adli et al., 2010), enabling the investigation of
chromatin remodeling that might occur in HSCs maintained ex vivo by CR culture.
Ribosomal profiling may also eventually be informative of transcriptome-wide ribosome
occupancy, although the technology currently requires orders of magnitude more cells
than is possible to perform on such a rare population (Hsieh et al., 2012).
The transcriptional profile of HSCs maintained ex vivo under defined conditions
would be an informative resource in ongoing efforts to define the regulatory network that
promotes retention of HSC function. Although I have not yet achieved this goal, my efforts
so far have yielded valuable insight into the technical considerations of such an
undertaking, allowing me to propose detailed methodology for how this might be
completed in the future. The method described here is moreover broadly applicable to
biologically relevant conditions that yield limiting quantities of RNA or differing
quantities of RNA between samples.
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Figure 3.1: Reduced RNA content in cultured HSCs. (A) RNA was isolated from
freshly sorted HSCs and HPCs. Total RNA content was measured by nanofluidic
electrophoresis. (B) Cellular RNA was isolated with spiked-in YFP mRNA from freshly
sorted HSCs and from HSCs following 3 days culture. Total RNA content was measured
by nanofluidic electrophoresis. The peak at ~900 nt indicates the spiked-in mRNA, while
peaks at 2000 nt and 4000 nt indicate 18S and 28S rRNA, respectively (or lack thereof).
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Figure 3.2: PCA of RNA-seq on HSCs maintained ex vivo. (A,B) RNA was isolated
from freshly sorted HSCs and from HSCs following 3 days cytokine-free culture in DMSO,
CHIR99021, rapamycin, or CR. RNA was amplified and RNA-seq was performed on five
biological replicates. PCA was applied to all samples (A) and following exclusion of outlier
samples (B). Each sphere represents an individual sample from one replicate.
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Figure 3.3: Gene expression profile analysis.
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Figure 3.3: Gene expression profile analysis. (A) RNA-seq was performed on RNA
isolated from uncultured HSCs and from HSCs following 3 days cytokine-free culture in
vehicle, CHIR99021, rapamycin, or both. Genes of interest were identified as those whose
expression level was 1) <1.2-fold different in CR-cultured HSCs compared to uncultured
HSCs, and 2) ≥1.5-fold different in CR-cultured HSCs compared to control-cultured HSCs.
One hundred forty-three genes fulfilled these criteria. Based on their reported functions,
about half of these genes grouped into the categories shown. (B) RT-PCR was performed
on two biological replicates (right panels) to validate genes of interest identified by IPA of
RNA-seq (left panels).
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Figure 3.4: Verifying aRNA amplification method. (A,B) Total RNA was isolated
from 650 HPCs, serially diluted, and subjected to three rounds of aRNA amplification.
aRNA concentration was quantified by spectrophotometry (A), and relative transcript
abundance of several genes following amplification was measured by RT-PCR (B).
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CHAPTER 4: AUTOPHAGY IS A SIGNATURE OF A SIGNALING NETWORK
THAT MAINTAINS HSCS
The data presented in this chapter are in revision at PLoS One.
Introduction
Stem cells are defined by the ability to both self-renew and generate differentiated
cells, enabling them to regenerate tissues under steady-state conditions and in response
to injury. This essential function in lifelong tissue maintenance endows stem cells with
exceptional potential for clinical applications. HSCs, for example, are responsible for
maintaining the blood, and are used for the treatment of both congenital and acquired
hematological disorders (Purton and Scadden, 2007. While tremendous progress has been
made toward optimizing therapeutic use of HSCs, this is a rare population. Efforts to
expand HSCs ex vivo, for example for umbilical cord transplants or for therapeutic
genome editing, have been hampered by an incomplete understanding of the signaling
networks that regulate HSC fate decisions and subsequent difficulty defining conditions
that maintain HSC function beyond the niche (Lymperi et al., 2010).
HSCs reside in a low-perfusion niche (Parmar et al., 2007; Simsek et al., 2010;
Spencer et al., 2014), underscoring nutrient-sensing as an essential function. The
evolutionarily conserved nutrient sensor mTORC1 antagonizes HSC function, as
interventions that activate mTORC1, including loss of the negative regulators Pten (Yilmaz
et al., 2006), Gsk3 (Huang et al., 2009), and Tsc1 (Gan et al., 2008), lead to HSC
proliferation followed by exhaustion and in some cases leukemogenesis (Yilmaz et al.,
2006; Guezguez et al., 2016). Developing a thorough understanding of mediators of
mTORC1 signaling in this context will therefore be a critical step toward expansion of
functional HSCs ex vivo.
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mTORC1 regulates cell growth and proliferation through multiple effectors. The
relative importance of each of these effectors to HSC function and fate decisions remains
unclear. The best-characterized output of mTORC1 activation is the regulation of
translation via activation of S6 kinase (S6K) (Isotani et al., 1999) and inhibition of eIF4E
binding protein (4E-BP) (Gingras et al., 1999). HSCs require a precise level of translation:
they exhibit a low basal rate of translation compared to more differentiated hematopoietic
cell populations, and either increasing or decreasing this rate impairs their engraftment
upon transplantation (Signer et al., 2014). mTORC1 additionally promotes mitochondrial
biogenesis through both translation-dependent (Morita et al., 2013) and -independent
(Cunningham et al., 2007; Blattler et al., 2012) mechanisms. HSCs have been reported to
have lower mitochondrial mass and membrane potential than other hematopoietic
populations, with increases in these features correlating with loss of self-renewal capacity
(Mantel et al., 2010).
mTORC1 also suppresses autophagy, which is both a pro-survival mechanism in
the context of nutrient starvation and an important quality control system in the turnover
of old or damaged proteins and organelles. Autophagy is therefore a critical component of
stem cell maintenance, differentiation, and aging (Guan et al., 2013), and disruption of
this pathway has been linked to loss of function of a variety of stem cell populations,
including embryonic, epidermal (Salemi et al., 2012), skeletal muscle (Tang and Rando
2014; Garcia-Prat et al., 2016), neural (Vazquez et al., 2012; Wu et al., 2016), and
hematopoietic (Mortensen et al., 2011; Ho et al., 2017) stem cells. In the hematopoietic
system, loss of the essential autophagy genes Atg7 or Atg5 impairs HSC function while
promoting proliferation of hematopoietic progenitor cells, leading to bone marrow failure
(Mortensen et al., 2011; Watson et al., 2015). Moreover, highlighting the essential role of
nutrient-sensing in the reduced-perfusion HSC niche, HSCs activate autophagy to survive
55

cytokine starvation, while progenitors fail to activate autophagy and instead undergo
apoptosis (Warr et al., 2013). These findings indicate a unique requirement for autophagy
in the function of HSCs as opposed to other hematopoietic cell populations.
Despite the extensive body of literature characterizing these distinct outputs of
mTORC1 signaling in HSCs, the role of each in HSC maintenance remains unclear. The
complexity of the HSC niche and consequent challenge maintaining HSCs ex vivo have
constrained efforts to address this question. Previous work from our laboratory showed
that HSCs are maintained ex vivo in cytokine-free conditions when GSK-3 and mTORC1
are inhibited (Huang et al., 2012). Inhibition of GSK-3 activates downstream Wnt/βcatenin signaling, and β-catenin is required for HSC maintenance in this setting, but the
pathway(s) downstream of mTORC1 that contribute to this response have not been
identified. We have investigated the complex signaling network downstream of mTORC1
associated with the maintenance of long-term HSCs. We find that activation of autophagy
is uniquely associated with conditions that maintain self-renewing HSCs.
Cell-autonomous regulation of HSC function by GSK-3 and mTORC1
We previously reported that simultaneous GSK-3 and mTORC1 inhibition
maintains HSC function ex vivo in HSPCs (Lin-Sca1+c-Kit+ [LSK]) (Huang et al., 2012).
While this fraction is enriched for HSCs, it is a heterogeneous population composed
primarily of progenitor cells. To address a potential indirect effect of modulating GSK-3
and mTORC1, we sorted HSCs (LSK-CD48-CD150+ [LSK-SLAM]) and cultured them in
serum-free, cytokine-free medium in the presence or absence of the GSK-3 inhibitor
CHIR99021 and rapamycin (CR). Cell number did not significantly change during culture,
and ~87% of cells remained viable after 7 d of culture (Figure 4.1A,B). To assess HSC
function, we performed a competitive repopulation assay. CD45.1 + HSCs cultured in
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vehicle or CR for 7 d were injected with CD45.2+ competitor whole bone marrow cells into
lethally irradiated recipients. HSCs cultured with CR retained both multilineage and longterm (up to 24 weeks) engraftment potential, while control cultured cells failed to engraft
(Figure 4.1C,D). These results indicate that GSK-3 and mTORC1 inhibition maintains
stem cell function by acting directly on HSCs.
mTORC1 activity and global translation during HSC maintenance
mTORC1 regulates cell growth and metabolism through multiple independent
effectors, the best-characterized of which is promotion of translation through activation
of S6K and inhibition of 4E-BP. As HSCs require a precise level of translation (Signer et
al., 2014), we further explored the regulation of S6 and 4E-BP in cultured HSCs. The
canonical readout for mTORC1 activity and regulation of translation is therefore
measurement of phospho-S6 (pS6) and phospho-4E-BP1 (p4E-BP1) levels, which we
assessed over time in LSK-CD48- cells. (The CD150 epitope is destroyed during fixation
and permeabilization [Kalaitzidis and Neel, 2008].) GSK-3 suppresses mTORC1, and
GSK-3 inhibition therefore activates mTORC1 (Inoki et al., 2006; Huang et al., 2009;
Huang et al., 2012). Although we did not observe an effect on pS6 or p4E-BP1 using the
inhibitors at our standard concentrations for HSC culture, CHIR99021 and rapamycin are
typically used at three and 100 times higher concentrations, respectively. A
correspondingly higher concentration of GSK-3 inhibitor increases phosphorylation of S6
in LSK-CD48- cells, as shown by flow cytometric detection with a phospho-specific pS6
antibody (Figure 4.2A,B). Rapamycin inhibits S6 phosphorylation, as expected, and
attenuates but does not completely inhibit increased S6 phosphorylation when combined
with CHIR99021 (Figure 4.2A,B). Rapamycin also reduces 4E-BP1 phosphorylation in
LSK-CD48- cells. We moreover observe a trend toward a further decrease in p4E-BP1 in
57

CR-treated cells, although the difference fails to reach statistical significance (Figure
4.2C,D). Simultaneous inhibition of GSK-3 and mTORC1 therefore achieves a level of
mTORC1 activity that is distinct from that following inhibition of either alone.
mTORC1 regulates translation in part via S6K promotion of ribosomal gene
transcription (Xiao and Grove, 2009). We therefore cultured c-Kit+ cells in vehicle,
CHIR99021 (3 µM), rapamycin (5 nM), or both for 24 h and measured the expression of
large and small ribosomal subunit protein genes by RT-PCR. CR-treated cells consistently
express higher levels of all ribosomal protein genes assessed when compared to control or
rapamycin-treated cells, and in most cases compared to CHIR99021-treated cells as well
(Figure 4.2E). Importantly, ribosomal RNA expression is equal across conditions
(Figure 4.2F). Together, these results demonstrate a specific enrichment for expression
of ribosomal protein genes in CR-treated HSPCs, suggesting an elevated capacity for
protein biosynthesis.
The increased expression of ribosomal protein genes in CR-cultured HSCs was
unexpected, as we predicted that rapamycin would block mTORC1-dependent activation
of translation. However, the effective concentration of rapamycin in our culture system is
100-fold lower than typically used. To address translation directly, we measured the rate
of global protein synthesis by O-propargyl-puromycin (OP-Puro) incorporation into
nascent polypeptides and fluorescent labeling (Liu et al., 2012) followed by flow cytometric
analysis. We find a stepwise increase in the rate of translation as HSCs differentiate into
more committed progenitor populations (Supplementary Figure 4.1A), as previously
reported (Signer et al., 2014). We next measured OP-Puro incorporation in LSK-CD48cells after 3 h and 24 h culture with or without inhibitors. Bulk protein synthesis is elevated
in CHIR99021-treated cells compared to cells cultured with DMSO or rapamycin alone,
consistent with mTORC1 and S6K activation. However, protein synthesis was also
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increased in CR-treated cells (Figure 4.2G, Supplementary Figure 4.1B); while this
finding is consistent with the increased pS6 and increased ribosomal protein expression
observed in CR, it is not consistent with suppression of global protein synthesis as a
mechanism for CR maintenance of HSCs.
Targeting S6K and eIF4E downstream of mTORC1 in HSC maintenance
While these findings argue against suppression of protein synthesis as a
mechanism of HSC maintenance ex vivo, we could not rule it out completely. We sought
to address this possibility further by more specifically inhibiting S6K and/or eIF4E. To
achieve targeted inhibition of S6 and 4E-BP, as opposed to broader inhibition of mTORC1,
we replaced rapamycin in CR culture with the S6K inhibitor PF-4708671, the eIF4E
inhibitor 4EGI-1, or both (Figure 4.3A). If rapamycin supports HSC maintenance by
inhibiting translation, then an S6K or eIF4E inhibitor should substitute for rapamycin.
PF-4709671 effectively inhibits S6K, as measured by reduced S6 phosphorylation in
phospho-flow cytometry (Figure 4.3B, Supplementary Figure 4.1C), while 4EGI-1
reduces the rate of bulk protein synthesis (Figure 4.3C, Supplementary Figure
4.1D). However, it should be noted that the dose of 4EGI-1 that achieves reduced
translation also approaches the limit of toxicity (Moerke et al., 2007).
To test whether inhibition of either of these pathways downstream of mTORC1 is
sufficient to maintain HSC function, we sorted HSPCs and cultured for 7 d in CHIR99021
plus PF-4708671, 4EGI-1, or both, followed by competitive transplant. While CR-cultured
cells engrafted, we detected no chimerism in recipients of any cells cultured without
rapamycin (Figure 4.3D). We conclude that combined inhibition of S6K and eIF4E
downstream of mTORC1 is not sufficient to maintain HSC function. Taken together with
our findings that CR increases expression of ribosomal protein genes and the rate of global
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translation, these data argue against inhibition of protein synthesis as a mechanism for
maintaining HSCs in cytokine-free culture.
Mitochondrial mass and activity in maintained HSCs
In addition to translation, mTORC1 is a known regulator of mitochondria. While
mTORC1-driven translation contributes to mitochondrial biogenesis (Morita et al., 2013),
mTORC1 also regulates mitochondrial membrane potential and oxidative capacity
independently of translation (Schieke et al., 2006; Cunningham et al., 2007). As low
mitochondrial mass and membrane potential have been correlated with HSC function
(Mantel et al., 2010; Sukumar et al., 2016), we explored how GSK-3 and mTORC1
inhibition might affect mitochondria in HSC maintenance. We first measured total
mitochondrial mass by MitoTracker Green in the LSK-CD48- fraction of lineage-depleted
bone marrow cells after 16 h culture. Cells treated with CHIR99021 either alone or in
combination with rapamycin exhibit an increase in mitochondrial mass (Figure 4.4A),
consistent with the CHIR99021-mediated increase in translation (Figure 4.2G,
Supplementary Figure 4.1B). However, while mitochondrial mass is generally low in
HSCs compared to non-self-renewing progenitors (Mantel et al., 2010; Sukumar et al.,
2016), the increase in CR-maintained HSCs argues against a role for mitochondrial mass
in the maintenance of HSCs cultured in CR.
In addition to increased mitochondrial mass, increased mitochondrial membrane
potential correlates with loss of long-term repopulating capacity of HSCs (Mantel et al.,
2010). We therefore assessed mitochondrial membrane potential, which could allow for
the observed maintenance of stemness despite elevated mitochondrial mass in CRcultured HSCs. Following 16 h culture, we measured mitochondrial membrane potential
in LSK-CD48- cells using JC-1, a positively charged dye that accumulates in the negatively
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charged matrix of polarized mitochondria in a potential-dependent manner (Reers et al.,
1991). While heterogeneous lineage-depleted bone marrow cells exhibit a distribution
between populations of high and low membrane potential, LSK-CD48- cells in all culture
conditions are overwhelmingly in the low membrane potential fraction (Figure 4.4B).
Thus CR culture increases mitochondrial mass but maintains low mitochondrial
membrane potential, compatible with the maintenance of HSC function.
Reduced cell volume and RNA content in cultured HSCs
mTORC1 integrates nutrient availability and mitogenic stimuli to direct activity of
biosynthetic and catabolic pathways, and is thus a major regulator of cell size (Lloyd,
2013). Our culture conditions lack serum or exogenous cytokines, known activators of
mTORC1, and maintenance of HSCs depends on addition of the mTORC1 inhibitor
rapamycin. We therefore assessed cell size following culture of purified HSCs in vehicle,
CHIR99021, rapamycin, or CR. By 3 d in culture, all cells were visibly smaller than freshly
isolated HSCs (Supplementary Figure 4.2A). We measured cell area on each day of
culture using a micrometer and ImageJ software. Mean cell volume decreased 60% in
control, rapamycin, and CR-cultured cells and 45% in CHIR99021-treated cells
(Supplementary Figure 4.2B).
Ribosome biogenesis and protein synthesis are among the most energy-consuming
cellular processes. These pathways must therefore be tightly regulated based upon
nutrient availability. As cell size generally correlates with ribosome biogenesis (Cook and
Tyers, 2007), we measured total RNA content in HSCs by nanofluidic electrophoresis
before and after 3 d culture. RNA was readily detected in uncultured HSCs, but
undetectable in an equal number of cultured cells (Supplementary Figure 4.2C). The
low RNA content was confirmed by flow cytometry. We cultured lineage-depleted bone
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marrow cells in vehicle, CHIR99021, rapamycin, or both. After 3 d, we performed flow
cytometric analysis for DNA content by Hoechst 33342 and for RNA content by pyronin Y
in the HSPC fraction. While freshly isolated HSPCs display a clear distribution through
the cell cycle, cells cultured under any condition are overwhelmingly in G0 with markedly
reduced total RNA content (Supplementary Figure 4.2D). We therefore conclude that
GSK-3 and mTORC1 inhibition maintains HSC function in cells that have entered a
quiescent state.
Autophagy as a molecular mark of HSC maintenance
Quiescent HSCs require autophagy to maintain their capacity for self-renewal; loss
of Atg7 stimulates proliferation of hematopoietic progenitors with a parallel loss of longterm HSCs, leading to a marked myeloproliferative state in vivo (Mortensen et al., 2011).
Furthermore, suppression of autophagy is a major downstream function of mTORC1, and
inhibition of mTORC1 with rapamycin activates autophagy, although typically at
concentrations 100 times higher than used here. To examine whether activation of
autophagy is specifically associated with maintenance of functional HSCs in culture (e.g.,
cultured in CR), we performed RT-PCR for a pro-autophagic gene expression signature
(Warr et al., 2013) in cKit+ cells cultured for 24 h in DMSO, CHIR99021, rapamycin, or
CR. Compared to cells cultured under control conditions, cells cultured in CR express
significantly higher levels of multiple markers of autophagy, including Atg4b, Bnip3, and
Gabarap, with Prkaa2 and Sesn2 exhibiting a trend toward higher expression in CR
(Figure 4.5A). Notably, expression of these markers is higher in CR than in cells treated
with rapamycin alone. This gene signature is consistent with unique activation of
autophagy under conditions (simultaneous inhibition of GSK-3 and mTORC1) that
maintain functional HSCs in culture.
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To confirm activation of autophagy in CR-cultured HSCs, we examined the
formation of autophagosomes. As a transition from diffuse to punctate staining for LC3 is
a hallmark of autophagosome assembly and activation of autophagy (Kabeya et al., 2000;
Tang and Rando, 2014), we performed immunofluorescence staining for LC3 puncta in
HSCs cultured for 16 h (Figure 4.5B). CR-maintained HSCs exhibited significantly more
LC3-puncta-positive cells (Figure 4.5C) and on average more LC3 puncta per cell
(Figure 4.5D) compared to vehicle, CHIR99021-, or rapamycin-treated controls. Taken
together with the autophagy gene signature, these results demonstrate that activated
autophagy is uniquely enhanced in conditions that maintain HSCs.
Conclusion
mTORC1 regulates cell metabolism and proliferation through multiple pathways.
Extensive evidence suggests that mTORC1 activation promotes HSC lineage commitment
at the expense of self-renewal (Yilmaz et al., 2006; Chen et al., 2008; Huang et al., 2009;
Kharas et al., 2009), but the downstream pathways mediating this effect remain
undefined. We have investigated multiple downstream mTORC1 targets to assess which
pathways are uniquely activated or inhibited when the GSK-3 and mTORC1 pathways are
regulated to maintain HSCs. These studies reveal that autophagy strongly and uniquely
correlates with conditions that maintain HSC function ex vivo.
We identified a pro-autophagic phenotype by a gene expression signature and the
appearance of LC3+ autophagosomes. While mTORC1 is a well-characterized inhibitor of
autophagy, the dose of rapamycin used for these studies (5 nM) is significantly below the
100-500 nM reported to induce autophagy. Consistently, we only observe a significant
increase in autophagy-related gene expression in the presence of rapamycin and
CHIR99021 (Figure 4.5). GSK-3 is moreover an established negative regulator of
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mTORC1 (Inoki et al., 2006), and GSK-3 inhibition might therefore be predicted to block
autophagy. However, several compelling lines of evidence suggest a potential mechanism
for synergy between the combined inhibition of GSK-3 and mTORC1 to activate
autophagy. Recent work reports that GSK-3 inhibits lysosomal acidification
independently of mTORC1, blocking autophagy (Azoulay-Alfaguter et al., 2015). GSK-3
additionally inhibits autophagy independently of mTORC1 via phosphorylation and
cytosolic sequestration of TFEB, the master transcription factor of lysosomal biogenesis
(Parr et al., 2012; Marchand et al., 2015). Intriguingly, mTORC1 also inhibits autophagy
in part through blocking nuclear translocation of TFEB (Roczniak-Ferguson et al., 2012;
Settembre et al., 2012). It is therefore possible that combined inhibition of mTORC1 and
GSK-3 allows TFEB to translocate to the nucleus and activate autophagy.
These findings additionally build on a growing body of literature supporting an
essential role for autophagy in the maintenance, activation, and differentiation of multiple
stem cell populations, including embryonic, epidermal (Salemi et al., 2012), neural (Wu et
al., 2016), skeletal muscle (Tang and Rando, 2014; Garcia-Prat et al., 2016), and
hematopoietic stem cells (Mortensen et al., 2011; Warr et al., 2013; Ho et al., 2016). The
current speculative model in the field is that autophagy is a vital mechanism of protein
and organelle quality control that maintains low levels of reactive oxygen species and
protects stem cells from oxidative stress and DNA damage over the lifetime of the
organism (Phadwal et al., 2013; Schultz and Sinclair, 2016). As a primary purpose of
autophagy is to degrade cytoplasmic contents and generate an internal nutrient pool to
sustain protein synthesis during periods of nitrogen starvation (Yang et al., 2006),
autophagic recycling may also serve as an important source of amino acids for stem cells
residing in a low-perfusion, reduced-nutrient niche. On the other hand, autophagy can
promote stem cell activation and differentiation by degrading multipotency factors and
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providing biosynthetic materials to support the growth and proliferation required for
tissue regeneration (Vazquez et al., 2012; Guan et al., 2013; Tang and Rando, 2014). Stem
cell fate decisions may thus be directed in part by the extent or targets of autophagic
degradation.
In contrast, our results do not support a role for suppression of translation as a
mechanism to maintain HSC function ex vivo. HSCs maintained in CR display increased
ribosomal protein gene expression and an elevated rate of protein synthesis compared to
HSCs cultured in control medium or freshly isolated HSCs (Figure 4.2G,
Supplementary Figure 4.1B). S6K and eIF4E inhibitors correspondingly reduce S6
phosphorylation and the rate of translation but fail to recapitulate ex vivo HSC
maintenance when combined with GSK-3 inhibition (Figure 4.3). HSCs in vivo require
a tightly controlled rate of protein synthesis that is regulated in part by the translation
initiation inhibitor 4E-BP (Signer et al., 2014; Signer et al., 2016). The increase in bulk
translation that we observe in our cytokine-free, ex vivo HSC maintenance system may
therefore represent a homeostatic adjustment when HSCs are deprived of signals from
their normal microenvironment. It also remains possible that restricting translation may
be important to maintain long-term function when HSCs are stimulated to undergo selfrenewing cell divisions. However, taken together, our findings of increased global
translation in CR medium argue against a role for suppression of protein translation as a
mechanism for maintenance of HSCs in these ex vivo conditions.
We additionally observe a GSK-3-specific increase in mitochondrial mass in
cultured HSCs (Figure 4.4A). Like the elevated rate of translation, this is a surprising
result given that increasing mitochondrial mass has been correlated with loss of selfrenewing function in HSCs (Mantel et al., 2010). However, mitochondrial membrane
potential similarly correlates with HSC function (Mantel et al., 2010), and we find that this
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is maintained at low levels in functional HSCs ex vivo despite the increase in
mitochondrial mass. Our results therefore suggest that preserving the low mitochondrial
mass observed in uncultured HSCs is not required to maintain HSC function in CR culture.
All tested culture conditions cause a dramatic reduction in total RNA content and
cell size (Supplementary Figure 4.2), suggesting a global metabolic shutdown in HSCs
upon removal from the niche. At the same time, GSK-3 inhibition (alone or in combination
with rapamycin) induces an increase in total protein synthesis (Figure 4.2G,
Supplementary Figure 4.1B), consistent with mTORC1 activation, whereas combined
GSK-3 and mTORC1 inhibition uniquely activates autophagy. We speculate that
autophagy may provide the biosynthetic material required to support the elevated rate of
translation induced by CHIR99021. In this model, only cells that achieve the appropriate
balance between anabolism and catabolism resolve these antagonistic metabolic cues and
thereby retain self-renewing and multilineage repopulating capacity.
Finally, our studies reveal a signaling network that is sufficient to maintain HSCs
cell-autonomously. Extensive crosstalk occurs between HSCs and the microenvironment
in vivo to contribute to regulation of HSC activity. That progenitors are dispensable in this
model system indicates that cell-intrinsic regulation of GSK-3 and mTORC1 is sufficient
to maintain HSC function. This finding moreover highlights the potential value of this
culture system in characterizing the signaling network that regulates HSC fate decisions,
as this analysis would not have been possible to perform on HSCs in situ. How HSCs
respond to the altered environment outside of the niche is an important consideration as
researchers seek methods to expand HSCs to improve the efficacy of HSC transplants.
Our investigation assessed the responses of multiple mTORC1 targets in the
context of a signaling network that maintains HSCs. We identified autophagy as a key
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molecular marker of this signaling network. Future studies may reveal specific targets of
these pathways in the maintenance of HSC function.
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Figure 4.1: Cell-autonomous regulation of HSC function by GSK-3 and
mTORC1.
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Figure 4.1: Cell-autonomous regulation of HSC function by GSK-3 and
mTORC1. (A) HSCs were cultured for 3 d, and cell number relative to day 0 was
determined visually. (B) Viability of HSCs cultured in control medium or CR after 7 d
culture, determined by Trypan Blue exclusion. (C, D) HSCs were cultured for 7 d and then
transplanted with competitor cells into lethally irradiated hosts. Peripheral blood was
collected at 24 weeks post-transplant, and multilineage potential of donor-derived
(CD45.1+) cells was determined by flow cytometry for lineage-specific markers as indicated
(C). Data shown are from one recipient representative of CR-cultured HSCs. Long-term
engraftment of freshly isolated HSCs or of HSCs cultured in vehicle or CR was determined
by flow cytometry for donor-derived (CD45.1+) cells following competitive transplant (D).
Chimerism data shown were collected 24 weeks after transplant. Each symbol represents
the results from an individual mouse. Red dotted line indicates 5% threshold defining
recipients as positive for donor-derived engraftment. Error bars represent S.E.M.
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Figure 4.2: mTORC1 activity and global translation during HSC maintenance.
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Figure 4.2: mTORC1 activity and global translation during HSC maintenance.
(A-D) Representative flow cytometry histograms of pS6 (A) and p4E-BP1 (C) from 1.5 h
time point, and their median fluorescence intensities relative to DMSO (B, D), measured
by phospho-flow cytometry in the LSK-CD48- fraction of lineage-depleted bone marrow
cells at the indicated times after cells were isolated and placed into culture medium.
Asterisks indicate statistical significance for comparison of treatment to DMSO within the
same time point. (E, F) cKit+ cells were cultured for 24 h followed by RNA isolation for
RT-PCR analysis. RT-PCR for ribosomal protein (E) and ribosomal RNA (F) gene
expression relative to DMSO. (G) Lineage-depleted bone marrow cells were cultured for
24 h, and then rate of protein synthesis relative to DMSO was measured by incorporation
of OP-Puro followed by flow cytometric analysis of the LSK-CD48- fraction. Error bars
represent S.E.M. Statistical significance for gene expression analyses was assessed using
a one-way ANOVA followed by Dunnett’s test for multiple comparisons. Statistical
significance for pS6 and p4E-BP1 median fluorescence intensities was assessed using a
one-way ANOVA followed by Tukey’s test for multiple comparisons. * p < 0.05, ** p <
0.005.
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Figure 4.3: Targeting S6K and eIF4E downstream of mTORC1 in HSC
maintenance.
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Figure 4.3: Targeting S6K and eIF4E downstream of mTORC1 in HSC
maintenance. (A) Strategy to test inhibition of S6K or eIF4E in HSC culture: If the
primary effect of rapamycin in HSC maintenance is to inhibit S6K and/or eIF4E, then
direct inhibitors of these downstream effectors should be able to replace rapamycin and
suppress lineage commitment. (B) Flow cytometric analysis of pS6 in the LSK-CD48fraction of lineage-depleted bone marrow cells treated with PF-4708671. (C) Rate of
translation relative to vehicle in LSK-CD48- cells treated with 4EGI-1, measured by OPPuro incorporation. (D) HSPCs were cultured for 7 d and then transplanted with
competitor cells into lethally irradiated hosts. Donor-derived engraftment was determined
by flow cytometry for CD45.1+ cells in peripheral blood from recipients of cultured HSPCs
following competitive transplant. CP, CHIR99021 + PF-4708671; C4, CHIR99021 + 4EGI1; CP4, CHIR99021 + PF-4708671 + 4EGI-1. Chimerism data shown were collected 8
weeks after transplant and are representative of 4-5 recipient mice per group.
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Figure 4.4: Mitochondrial mass and activity in maintained HSCs.
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Figure 4.4: Mitochondrial mass and activity in maintained HSCs. (A, B) Flow
cytometric analysis of mitochondrial mass (median fluorescence intensity of Mitotracker
Green) relative to DMSO (A) and mitochondrial membrane potential (JC-1) (B) in the
LSK-CD48- fraction of lineage-depleted bone marrow cells following 16 h culture. Flow
cytometric data shown are representative results of 3 experiments. Error bars represent
S.E.M. Vm, mitochondrial membrane potential. Statistical significance was assessed using
a one-way ANOVA followed by Tukey’s test for multiple comparisons. * p < 0.05, ** p <
0.005.
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Figure 4.5: Autophagy as a molecular mark of HSC maintenance.
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Figure 4.5: Autophagy as a molecular mark of HSC maintenance. (A) RT-PCR
for a pro-autophagic gene signature relative to DMSO in c-Kit+ cells following 24 h culture.
(B-D) HSCs were cultured for 24 h and then fixed for immunofluorescence analysis of LC3
staining. Sample image of LC3-punctum-positive cell at 400× magnification (B). White
arrowhead indicates LC3 punctum. Scale bar, 10 μm. Quantification of percentage of LC3puncta-positive cells (C) and of average number of LC3 puncta per cell (D). Data shown
are average of 3-4 experiments. Error bars represent S.E.M. Statistical significance was
assessed using a one-way ANOVA followed by Dunnett’s test for multiple comparisons. **
p < 0.005, *** p < 0.0005.
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Supplementary Figure 4.1: HSPC populations display stepwise changes in
rate of protein synthesis.
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Supplementary Figure 4.1: HSPC populations display stepwise changes in
rate of protein synthesis. (A) Rate of protein synthesis determined by incorporation
of OP-Puro in freshly isolated HSPC populations relative to Lin+ cells. (B) Rate of protein
synthesis relative to DMSO in the LSK-CD48- fraction of lineage-depleted bone marrow
cells following 3 h culture. (C) Flow cytometric analysis of pS6 in the LSK-CD48- fraction
of lineage-depleted bone marrow cells treated with PF-4708671 and/or stem cell factor
(SCF) (100 ng/ml). (D) Flow cytometric analysis of relative rate of protein synthesis in the
LSK-CD48- fraction of lineage-depleted bone marrow cells treated with 4EGI-1. Error bars
represent S.E.M. Statistical significance was assessed using a one-way ANOVA followed
by Tukey’s test for multiple comparisons. * p < 0.05, ** p < 0.005.
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Supplementary Figure 4.2: Reduced cell volume and RNA content in cultured
HSCs.
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Supplementary Figure 4.2: Reduced cell volume and RNA content in cultured
HSCs. (A,B) HSC size by phase contrast microscopy of freshly isolated cells and after 3 d
culture (A) and corresponding volume relative to day 0 over time (B). n = 40 – 60 cells
counted per treatment group per day; **** indicates p < 1.5 × 10 -18 for all conditions
compared to day 0 (Student’s t-test). Images 400× magnification. Scale bar, 20 μm. (C)
RNA was isolated from fresh HSCs and from HSCs following 3 d culture. Total RNA
content was measured by nanofluidic analysis with up to 70% recovery of spiked-in RNA.
(D) RNA content was measured by flow cytometric analysis in the HSPC fraction of
lineage-depleted bone marrow cells that were freshly isolated and after 3 d culture. Data
shown are representative results of 3-5 experiments. Error bars represent S.E.M.
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CHAPTER 5: CONCLUSIONS AND FUTURE DIRECTIONS
Introduction
HSCs have a long history of use in the clinic for the treatment of congenital and
acquired hematological malignancies and disorders, yet their full clinical potential
remains constrained by an incomplete understanding of their underlying biology (as
reviewed in Chapter 1). Major limiting factors in the thorough characterization of the HSC
regulatory network include the complexity of the HSC niche and the rarity of the
population, which present significant biological and technical challenges. In this
dissertation, I characterized a signaling network that maintains HSCs under defined
conditions and identified enhanced autophagy as a signature of this state.
I contributed to the identification of a signaling network that maintains HSCs ex
vivo through the simultaneous inhibition of GSK-3 and mTORC1 (Chapter 2). I showed
that HSPCs cultured with inhibitors of GSK-3 and mTORC1 (CR) in the absence of serum
or exogenous cytokines retained multilineage potential, providing initial proof of principle
that GSK-3 and mTORC1 inhibition maintains HSC function ex vivo. I additionally
demonstrated activation of a Wnt target gene by GSK-3 inhibition, consistent with
subsequent work by the first author that β-catenin is required for this ex vivo maintenance
(Huang et al., 2012).
I followed up this work by attempting to perform transcriptional profiling of HSCs
maintained ex vivo (Chapter 3). Initial efforts to perform this analysis revealed an
unexpected massive decrease in RNA content of cultured compared to freshly isolated
HSCs. I therefore investigated approaches to overcome this technical hurdle, and
presented a detailed method suitable to perform gene expression profiling comparing
uncultured and cultured HSCs. If completed, this profile could serve as a valuable
resource to identify transcriptional features that mark the state of HSC maintenance. It
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could moreover reveal how HSCs adjust to conditions beyond the niche, providing insight
into how one could uncouple proliferation from differentiation to drive self-renewing
divisions. Ex vivo expansion of HSCs would both facilitate further molecular
characterization of HSCs and accelerate broader clinical use of HSCs, such as for
therapeutic gene editing.
Finally, I assessed multiple outputs of mTORC1 signaling to assess which pathways
are uniquely activated or inhibited when GSK-3 and mTORC1 activity is suppressed to
maintain HSCs. This investigation revealed that although the rate of global translation and
mitochondrial mass increase in a GSK-3 specific manner, enhanced activation of
autophagy is a unique molecular signature of HSCs maintained ex vivo (Chapter 4). This
finding is consistent with a growing body of literature describing an essential role for
autophagy in stem cell function. As more refined tools to assess autophagic degradation
are described, specific targets of autophagy in HSC maintenance may be identified.
Is autophagy required for HSC maintenance ex vivo?
The results described in Chapter 4 identify enhanced activation of autophagy as a
marker of HSC maintenance ex vivo, but they do not indicate whether it is required
downstream of mTORC1. This is a complicated question to address, as knockout of any of
several key components of the autophagy machinery leads to rapid myeloproliferation and
HSC exhaustion (Mortensen et al., 2011; Watson et al., 2015; Ho et al., 2017). We would
therefore predict that Atg5 or Atg7 knockdown during CR culture would not be
informative: lack of engraftment of such cells upon transplant could indicate a
requirement for autophagy in CR-mediated HSC maintenance, but it would also be
consistent with autophagy acting in parallel with the mechanism of CR maintenance.
However, if Atg5/7-knockdown HSCs cultured in CR did reconstitute the hematopoietic
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systems of transplant recipients, it would show that autophagy is unexpectedly not
required for GSK-3- and mTORC1-mediated maintenance of HSCs ex vivo.
We have observed that CR-cultured HSCs do not form colonies in colony-forming
assays (with Dheeraj Bhavanasi; data not shown), even though they give rise to long-term
multilineage engraftment upon transplant (Chapter 4). Accumulating evidence indicates
that autophagy promotes HSC quiescence (Mortensen et al., 2011; Watson et al., 2015; Ho
et al., 2017). Since CR-cultured HSCs exhibit enhanced autophagy (Chapter 4), it is
possible that autophagy maintains cultured HSCs in a quiescent state that renders them
incapable of forming colonies. (According to this model, the HSC niche of transplant
recipients provides the appropriate cues to suppress autophagy and activate CR-cultured
HSCs.) Briefly suppressing autophagy (for perhaps 1-2 days) following CR maintenance
may therefore activate quiescent cultured HSCs. Transient inhibition of autophagy could
be achieved pharmacologically by inhibitors of the required autophagy proteins Vps34
(Ronan et al., 2014) or Ulk1 (Egan et al., 2015), or genetically by Atg5/7 shRNA or
inducible CRISPR interference (Mandegar et al., 2016). If HSCs cultured in CR and then
briefly exposed to an autophagy-inhibiting agent gave rise to colonies, then it would
indicate that GSK-3 and mTORC1 inhibition maintains HSCs in a quiescent state that is
dependent upon activation of autophagy.
Autophagy is essential to the function of diverse stem cell populations, including
embryonic, epidermal (Salemi et al., 2012), skeletal muscle (Tang and Rando, 2014;
Garcia-Prat et al., 2016), neural (Vazquez et al., 2012; Wu et al., 2016), and hematopoietic
stem cells (Mortensen et al., 2011; Watson et al., 2015; Warr et al., 2013). Accumulating
evidence specifically supports a role for autophagy in HSC quiescence (Mortensen et al.,
2011; Ho et al., 2017). Autophagy is also upregulated during induction of quiescence in
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crustacean diapause embryos (Lin et al., 2016). The experiments proposed here will define
a role for autophagy in HSC quiescence and activation.
How does simultaneous GSK-3 and mTORC1 inhibition activate autophagy?
mTORC1 inhibits autophagy, and correspondingly, inhibition of mTORC1 by
rapamycin is a known inducer of autophagy. However, activation of autophagy requires
rapamycin concentrations of 100-500 nM, significantly greater than the 5 nM used in
combination with GSK-3 inhibition to maintain HSCs ex vivo. Rapamycin at 5 nM was not
sufficient to activate autophagy by itself (Figure 4.5), and therefore an alternative
mechanism is necessary to explain the effects we observe.
GSK-3 and mTORC1 both inhibit autophagy in part by promoting cytosolic
sequestration of the lysosomal and autophagy master TF TFEB (Parr et al., 2012;
Roczniak-Ferguson et al., 2012). As we only observe enhanced activation of autophagy in
HSCs cultured with both inhibitors, it suggests that combined inhibition of GSK-3 and
mTORC1 may allow TFEB to translocate to the nucleus and promote autophagy.
Immunofluorescence analysis for the subcellular localization of TFEB would address this
question, with the prediction that TFEB localization in the nucleus would be enhanced in
CR-cultured HSCs compared to vehicle- or single-treated HSCs. This model also predicts
that CR-cultured HSCs will express the highest levels of TFEB target genes, including
Atg9b, Maplc3b, and Sqstm1 (Settembre et al., 2011), which encode components of the
core autophagy machinery.
Finally, hepatocytes express higher levels of TFEB target genes in response to
treatment with the mTORC1 inhibitor Torin 1, but this effect is blunted in Tfeb-knockout
cells (Settembre et al., 2012). This result identifies TFEB as a main mediator of this
response. I have hypothesized that TFEB regulation may be an important mechanism by
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which GSK-3 and mTORC1 inhibition activates autophagy in HSC maintenance. If this is
the case, then Tfeb knockdown should block HSC maintenance in CR. Importantly, Tfebknockout cells in control medium do not express significantly different levels of target
genes compared to wild-type (Settembre et al., 2012), suggesting that Tfeb knockdown will
not affect HSC function except under conditions that induce autophagy.
GSK-3 or mTORC1 regulation of TFEB has been demonstrated in diverse cell types,
including HeLa (Settembre et al., 2012), mouse neuroblastoma (Parr et al., 2012), and
human pancreatic cancer (Marchand et al., 2015) cell lines. However, potential coregulation of TFEB by GSK-3 and mTORC1 has not been explored. GSK-3 and mTORC1
are established regulators of multiple stem cell populations (Welham et al., 2011; Ghosh
and Kapur, 2016; Tee et al., 2016). Autophagy is also increasingly recognized as an
essential process in stem cell function (Guan et al., 2013; Phadwal et al., 2013). If GSK-3
and mTORC1 inhibition promotes HSC maintenance through TFEB-mediated activation
of autophagy, a similar mechanism may function in additional stem cell populations. For
example, epidermal stem cells with excessive Wnt signaling exhibit transient expansion
followed by mTORC1-dependent depletion (Castilho et al., 2009), a phenotype remarkably
like that observed in HSCs (Huang et al., 2009). Refinement to the molecular level of
regulation of autophagy in stem cells may reveal valuable targets in senescence and
disease.
Does selective autophagy contribute to HSC maintenance?
I reported the expression of a pro-autophagic gene signature and the increased
formation of LC3+ autophagic puncta in HSCs maintained ex vivo (described in Chapter
4). Although this is sufficient to indicate generally that autophagy (macroautophagy) is
uniquely enhanced in these cells, additional observations leave open the possibility that
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forms of targeted autophagy may contribute to HSC maintenance ex vivo. The literature
on selective autophagy is limited. However, the selective autophagic degradation of
ribosomes and mitochondria (ribophagy and mitophagy, respectively) may play important
roles in sustaining HSC function.
Cellular RNAs are subject to extensive quality controls, with mRNA turnover
mediated primarily by ribonucleases (RNases) following removal of the 5’ cap and poly(A)
tail (Chen and Shyu, 2011). rRNA, however, which comprises the majority of cellular RNA,
is typically highly structured and bound in RNA-protein complexes, rendering it less
accessible to basic RNA degradation machinery. A lysosome-dependent increase in total
RNA turnover in serum-deprived human fibroblasts (Sameshima et al., 1981) and in
amino acid-deprived rat hepatocytes (Lardeux and Mortimore, 1987) provided early
evidence that autophagy might promote more large-scale RNA decay during starvation.
Further supporting a role for autophagy-mediated RNA degradation, the evolutionarily
conserved and broadly expressed T2 family of RNases is primarily localized to the
lysosome, with an optimal pH of 4-5 (Irie, 1999). A requirement for the T2 family of
RNases in RNA turnover has been described in Drosophila (Ambrosio et al., 2014),
zebrafish (Haud et al., 2011), and human (Henneke et al., 2009). Evidence of ribophagy
has since been reported in organisms from yeast (Kraft et al., 2008) to humans (Kristensen
et al., 2008). Notably, ribophagy requires components both of the core macroautophagic
machinery and of additional receptors that recognize targeted cargo and link it to
autophagosomal membranes (Frankel et al., 2016). Evidence of activated macroautophagy
may be therefore be consistent with activated ribophagy.
HSCs maintained ex vivo contain less total RNA and exhibit enhanced activation
of autophagy. These observations suggest that ribophagy may be a component of the
activated autophagy that marks HSCs maintained ex vivo. Ribosome biogenesis and
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protein synthesis are among the most energy-consuming cellular processes, and must
therefore be tightly regulated by nutrient availability. HSCs in vivo reside in a lowperfusion niche (Parmar et al., 2007; Simsek et al., 2010; Spencer et al., 2014) and require
a restricted rate of translation (Signer et al., 2014). Ribophagy is induced upon nutrient
deprivation (Kraft et al., 2008; Kristensen et al., 2008), consistent with the Klein
laboratory’s serum-free culture conditions. Combined, these observations make ribophagy
an attractive mechanism by which HSCs might suppress anabolism under conditions of
restricted nutrient availability, such as in ex vivo maintenance. Although I observed
reduced RNA content in all cultured cells, the hypothesis of ribophagy induction is
consistent with the enhanced activation of macroautophagy correlating uniquely with
conditions that maintain HSCs.
Although ribophagy appears to involve proteins that do not participate in
macroautophagy (Frankel et al., 2016), specific markers of mammalian ribophagy have
not been identified. When they are identified, it will become possible to study ribophagy
dynamics (e.g., through knockdown of ribophagy-specific adaptors) without interfering
with macroautophagy. Until then, indirect readouts must be employed. Expression of the
T2 family of RNases increases in response to nutrient deprivation (Ambrosio et al., 2014),
and its loss leads to accumulation of undigested rRNA in lysosomes (Haud et al., 2011).
Increased expression of Rnaset2 family members in cultured HSCs would therefore be
consistent with enhanced ribophagy. In addition, electron microscopy has been used to
visualize ribosomes in autophagosomes and lysosomes (Frankel et al., 2016). Although
this observation alone can be consistent with macroautophagy without invoking
ribophagy, analysis of protein turnover during amino acid starvation reveals distinct
kinetics of autophagic degradation of ribosomes compared to other cellular components,
suggesting temporal selection of cargo (Kraft et al., 2008; Kristensen et al., 2008). These
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experiments would not definitively demonstrate activation of ribophagy, but they would
support a role for it in the larger context of activated autophagy and reduced RNA content.
Cells also restrict energy needs in the context of nutrient deprivation through the
selective autophagic degradation of mitochondria. Mitophagy additionally serves as the
key process for mitochondrial quality control and turnover (Okamoto, 2014). Like
ribophagy, mitophagy involves both the core autophagic machinery and receptors that
mediate specific cargo targeting to autophagosomes, although mitophagy-specific
markers have also not yet been identified. Increasing mitochondrial mass has been
correlated with loss of HSC function (Mantel et al., 2010). CR culture maintains HSCs ex
vivo despite inducing an increase in mitochondrial mass (as described in Chapter 4).
Given the concomitant increase in autophagy in these cells, mitophagy is an attractive
potential component of the mechanism by which CR maintains HSCs. Although CRcultured HSCs have higher overall mitochondrial mass compared to vehicle, activated
mitophagy would selectively degrade dysfunctional mitochondria. The improved health of
the remaining mitochondria may therefore permit retention of function in HSCs despite
elevated mitochondrial content.
As with ribophagy, mitophagy-specific markers have not yet been identified, so
circumstantial evidence for targeted mitophagy would need to be considered in the
broader context of nutrient availability and cellular function. Mitochondria must undergo
fission prior to engulfment in autophagosomes (Rimessi et al., 2013). The observation that
mitochondrial mass is elevated in CR-cultured HSCs was based on flow cytometric
quantification of MitoTracker staining, indicating total mitochondrial content but not the
size of individual mitochondria. It would therefore be informative to perform
immunofluorescence analysis of cultured HSCs to visualize the extent of mitochondrial
fission in cultured HSCs. Mitochondria are also readily visualized in autophagosomes by
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electron microscopy. Finally, immunofluorescence analysis could colocalize the outer
mitochondrial membrane protein TOM20 to the lysosome. Combined, these results would
be consistent with activation of mitophagy as a marker of HSC maintenance ex vivo and
suggest improved mitochondrial quality control as a potential mechanism, although
mitophagy markers will need to be identified to obtain definitive evidence.
Selective autophagy is a conserved mechanism of organelle quality control and
metabolic regulation during development, homeostasis, and regeneration (Okamoto,
2014). One of the most dramatic described examples of this is the elimination of ribosomes
and mitochondria during red blood cell maturation, which occurs in a manner dependent
on selective autophagy but not macroautophagy (Kundu et al., 2008). Characterization of
such targeted autophagic pathways in HSCs maintained ex vivo would offer a more refined
definition of a metabolic program that HSCs activate to retain their function.
When is restricted translation important for HSC maintenance?
Morrison and colleagues have reported that HSCs require a low rate of translation
in vivo compared to more differentiated hematopoietic cells, and that this is mediated in
part by the 4E-BPs (Signer et al., 2014; Signer et al., 2016). GSK-3 and mTORC1 inhibition
reduces 4E-BP phosphorylation and maintains HSCs ex vivo despite elevating the rate of
translation compared to controls (as detailed in Chapter 4). These findings therefore argue
for a context-dependent requirement for restricted protein synthesis in HSCs.
One possibility is that HSCs may rely on low levels of specific proteins rather than
on a globally low rate of translation. The extent to which the 4E-BPs restrict translation
appears to be context-dependent. The 4E-BPs generally have only a modest effect on the
rate of bulk translation (Lynch et al., 2004; Tahmasebi et al., et al., 2014) and specifically
restrict translation of mRNAs related to survival, proliferation (Topisirovic and
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Sonenberg, 2011), mitochondrial structures, and oxidative phosphorylation (Morita et al.,
2013). In HSCs, however, 4E-BP1/2 double knockout leads to ~25% increased global
protein synthesis compared to wild type (Signer et al., 2016). As simultaneous GSK-3 and
mTORC1 inhibition leads to reduced 4E-BP phosphorylation without a corresponding
reduction in the rate of bulk translation, it is possible that HSC maintenance under these
conditions is mediated by restricted translation of specific transcripts, but that this is not
detectable at the level of total protein synthesis. Immunoblotting for known targets of 4EBP-restricted translation would help address this question. On a proteomic scale,
ribosomal profiling may eventually identify 4E-BP-regulated transcripts in HSCs under
physiological and artificial settings, although this technology currently requires orders of
magnitude more cells than is possible to perform on such a rare population.
An additional possibility, which is not mutually exclusive with 4E-BP-restricted
translation of selected mRNAs, is that a low rate of translation may be important for
maintenance of long-term HSC function in the context of proliferation, such as in cytokine
culture. In support of this hypothesis, a small molecule screen was recently completed for
compounds that, in combination with CR and a limited cytokine cocktail (no serum), could
promote UCB HSC expansion ex vivo (Dheeraj Bhavanasi and Peter Klein, unpublished).
Under these conditions, the inhibitor of eIF4E-eIF4G interaction 4E1RCat induced 8- to
10-fold HSC expansion by immunophenotypic analysis and by limiting dilution analysis
in immunocompromised mice. It will therefore be important to measure the rate of
translation in these cells to explore what role protein synthesis may play in the
maintenance of HSCs undergoing cytokine-induced self-renewing division.
Restricted translation is an important mechanism of maintenance or quiescence in
embryonic stem cells (Sampath et al., 2008), satellite cells (Zismanov et al., 2016),
epidermal stem cells (Blanco et al., 2016), and diapaused blastocysts (Bulut-Karslioglu et
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al., 2016). HSCs in vivo additionally require a controlled rate of protein synthesis (Signer
et al., 2014). My findings do not, however, support a role for suppression of translation as
a mechanism to maintain HSCs in cytokine-free culture. Future studies may identify the
molecular mediators and functional contexts that determine when restricted protein
synthesis affects HSC function.
Revised model for GSK-3 and mTORC1 regulation of HSC maintenance
Autophagy is essential for restricting ROS accumulation and consequent DNA
damage, in part through mitochondrial quality control. Maintaining genomic integrity is
particularly consequential in quiescent stem cells, given their function in lifelong tissue
maintenance and their limited capacity to dilute cellular waste by division (Guan et al.,
2013). Loss of autophagy in HSCs leads to rapid accumulation of mitochondria, ROS, and
DNA damage, followed by myeloproliferation and loss of regenerative potential
(Mortensen et al., 2011). This is accompanied by increased glucose uptake, NADH and
ATP levels, and a shift from glycolysis to oxidative phosphorylation, metabolic features
indicating HSC activation (Ho et al., 2017). Mice lacking the mTORC1 inhibitor Tsc1
exhibit a similar phenotype (Chen et al., 2008). Antioxidant treatment restores HSC
quiescence and function, identifying ROS as an important regulator of HSC quiescence.
Considering these reports, the work in this dissertation describes the ex vivo
maintenance of HSCs exhibiting a seemingly paradoxical metabolic profile: these cells are
smaller and contain less total RNA than uncultured HSCs, consistent with a quiescent
state, yet they also translate more mRNA into protein and have higher mitochondrial
content, suggesting stem cell activation. I hypothesize that the enhanced activation of
autophagy in maintained HSCs resolves these antagonistic metabolic cues, achieving the
balance between biosynthetic and degradative processes necessary to preserve stem cell
92

function. GSK-3 (Parr et al., 2012; Marchand et al., 2015) and mTORC1 (RoczniakFerguson et al., 2012; Settembre et al., 2012) each inhibit nuclear translocation of TFEB.
TFEB is therefore an attractive potential mediator of the autophagy uniquely enhanced in
CR-cultured HSCs (Figure 5.1). More thorough analyses of the metabolic profile of HSCs
maintained ex vivo, such as those described above, would provide further evidence that
GSK-3 and mTORC1 inhibition maintains HSC function in cells that have entered a
quiescent state.
Conclusion
In this dissertation, I investigated a signaling network that maintains HSCs. in
attempting to perform gene expression profiling on these cells, I discovered that they
exhibit a significant reduction in total RNA content, leading to the description of a detailed
protocol that can be used to characterize the transcriptional profile of cells with limited or
differing quantities of RNA. My investigations additionally identified enhanced activation
of autophagy as a marker of this network. This work both reinforces the essential role
autophagy plays in stem cell maintenance and raises compelling questions about the
contribution of metabolism to stem cell function.
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Figure 5.1: Revised model for GSK-3 and mTORC1 regulation of HSCs. GSK-3
regulates two antagonistic pathways in HSCs. GSK-3 inhibition of Wnt/β-catenin
signaling inhibits self-renewal, while GSK-3 inhibition of mTORC1 promotes lineage
commitment. Inhibition of GSK-3 activates both pathways. Simultaneous inhibition of
GSK-3 and mTORC1 may therefore block HSC lineage commitment while promoting selfrenewal. GSK-3 and mTORC1 each independently inhibit TFEB. As autophagy activation
is uniquely enhanced in HSCs in which both GSK-3 and mTORC1 are inhibited, TFEB may
mediate of this effect.
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CHAPTER 6: METHODS AND MATERIALS
Mice
C57BL/6 wild-type (CD45.2+) and SJL (CD45.1+) congenic mice were obtained
from the Jackson Laboratory. Mice were bred in-house in a pathogen-free mouse facility
at the University of Pennsylvania. Transplant recipients were 8- to 10-week-old CD45.2+
females. Donor mice were 6- to 8-week-old CD45.1+ males. Animal experiments were
performed in accordance with guidelines approved by the Institutional Animal Care and
Use Committee (IACUC) at the University of Pennsylvania (IACUC protocol #80317).
Flow cytometric sorting and analysis of HSCs
Bone marrow cells were flushed from the tibias and femurs of mice with PBS
without calcium or magnesium. For detection of LSK cells, whole bone marrow cells were
incubated with biotin-conjugated monoclonal antibodies to the following lineage markers:
B220 (6B2), CD4 (GK1.5), CD8 (53-6.7), Gr1 (8C5), Mac1 (M1/70), Ter119 (Ter119), and
interleukin-7 receptor (IL-7R) (A7R34); FITC-conjugated antibody to Sca1 (Ly6A/E; D7)
and APC-conjugated antibody to c-Kit (ACK2). CD48 and CD150 were measured with PEconjugated antibody to CD48 (HM48-1) and PE Cy7-conjugated antibody to CD150 (TC1512F 12.2). All antibodies were purchased from eBioscience except for antibody CD150,
which was purchased from Biolegend. Biotin-conjugated lineage marker antibodies were
detected using streptavidin-conjugated PE Texas Red (ThermoFisher). Antibodies to
B220, CD4, CD8, Gr1, Mac1 and IL-7R were diluted 1:550. Antibodies to Ter119 and Gr1
were diluted 1:275. Antibodies to Sca1, c-Kit, CD48, and CD150 were diluted 1:80. Nonviable cells were excluded using the viability dye DAPI (1 μg ml−1). Cells were sorted with
a FACSAria (Becton Dickinson) automated cell sorter. Analyses were performed on a
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FACSCanto or LSR II flow cytometer (Becton Dickinson). Data were analyzed using
FlowJo software (Tree Star).
Cytokine-free HSC and HSPC culture
HSPCs were cultured as described previously [27]. Briefly, mouse bone marrow
cells were harvested and distributed into a single-cell suspension by gently drawing
through a 22-gauge needle. Red blood cells were lysed in ammonium chloride–potassium
(ACK) buffer. Lineage-depleted bone marrow cells were isolated by incubating whole bone
marrow with biotin-conjugated lineage marker antibodies indicated above followed by
incubation with Dynabeads M-280 Streptavidin (ThermoFisher) and separation with the
EasySep magnet (Stem Cell Technologies). c-Kit+ cells were purified with the MACS cell
separation kit (Miltenyi Biotec). Isolated HSCs and HSPCs were cultured in X-VIVO 15
(BioWhittaker) supplemented with 1% penicillin and streptomycin (Sigma). CHIR99021
and rapamycin (Cayman Chemical) reconstituted in DMSO were added to final
concentrations of 3 μM (CHIR99021) and 5 nM (rapamycin) for all experiments unless
otherwise indicated. For inhibition of S6K and eIF4E, cells were cultured in 3 μM
CHIR99021 combined with 10 μM PF-4708671 (Tocris Bioscience) reconstituted in
ethanol, 50 μM 4EGI-1 (Tocris Bioscience) reconstituted in DMSO, or both. Sorted cells
were distributed into 96-well plates with 100 μl medium. One-half volume of medium and
full drug volume were replaced every other day.
Long-term competitive repopulation assays
C57BL/6 (CD45.2+) recipient mice were lethally irradiated with a cesium-137
irradiator in two equal doses of 500 rads separated by at least 2 h. SJL (CD45.1 +) donor
cells were mixed with 3 × 105 competitor C57BL/6 bone marrow cells and injected into the
retro-orbital venous sinus of anesthetized recipients. Transplanted mice were given
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antibiotic-containing water for four weeks following irradiation. Beginning 4 weeks after
transplantation and continuing for 24 weeks, blood was collected from the tail veins of
recipient mice and analyzed by flow cytometry for the lineage markers Gr1 (8C5), Mac1
(M1/70), B220 (6B2), CD4 (L3T4), CD8 (Ly-3) (eBioscience) to monitor engraftment.
RNA-seq
HSCs were sorted and cultured as described above, and RNA was isolated as
described below. Ten microliters of RNA per sample was input to three rounds of the
aRNA amplification method (Morris et al., 2011). Following amplification, aRNA product
quality and quantity was checked by nanofluidic electrophoresis with the RNA 6000 Pico
kit on a 2100 Bioanalyzer (Agilent Technologies). aRNA was delivered to the Perelman
School of Medicine Next-Generation Sequencing core for library preparation and RNAseq. One-hundred-base-pair single read sequencing was performed on a HiSeq4000
(Illumina). Genome alignment and differential expression analysis was performed by the
Penn Molecular Profiling Facility.
RNA isolation and RT-PCR
Cultured c-Kit+ or LSK-SLAM cells were centrifuged, lysed in 350 μl RLT Plus Lysis
buffer with Reagent DX (Qiagen) and beta-mercaptoethanol (Sigma-Aldrich), and RNA
was isolated using the RNeasy Plus Micro kit (Qiagen) as indicated by the manufacturer.
For spike-in confirming successful RNA isolation from cultured cells, 150 ng YFP mRNA
was added at the time of lysis. RNA concentration was quantified on a NanoDrop 1000
(ThermoFisher). 50 ng total RNA per sample was used for first-strand cDNA synthesis
using SuperScript III reverse transcriptase (Invitrogen) as indicated by the manufacturer.
Relative gene expression was quantified on a 7900HT Fast Real-Time PCR System
(Applied Biosystems) using Power SYBR Green PCR Master Mix (Applied Biosystems).
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Expression levels of genes of interest were normalized to β-actin expression. RT-PCR
primers were designed using NCBI Primer-BLAST, and sequences are available upon
request.
RNA content analysis and cell size measurement
Lineage-depleted bone marrow cells were isolated for analysis of RNA content and
cell size on day 0 or after 3 d of culture. At the time of analysis, cells were washed with PBS
and stained in LIVE/DEAD Fixable Near IR Dead Cell Stain (ThermoFisher) as directed
by the manufacturer, washed, and stained for surface markers indicated. For RNA content
analysis by flow cytometry, cells were then washed, resuspended in 20 μg ml-1 Hoechst
33342 (Cell Signaling Technologies) with 50 μg ml-1 verapamil (Calbiochem) in PBS
supplemented with 3% fetal bovine serum (FBS; GE Healthcare Life Sciences), vortexed
briefly, and incubated covered at 37°C for 45 min. Pyronin Y (Sigma-Aldrich) was added
directly to a final concentration of 1 μg ml-1 and cells were briefly vortexed and incubated
covered at 37°C for an additional 15 min. Cells were washed and immediately analyzed by
flow cytometry.
For size measurement, HSCs were sorted and cultured as described above. Each
day, cells were imaged on a Nikon Diaphot microscope equipped with a Nikon DS-Fi1
camera and NIS-Elements F imaging software (Nikon). Cell cross-sectional area was
measured in ImageJ (NIH) calibrated to a micrometer, and volume was calculated
assuming that cells are spherical.
Assessment of pS6 and p4E-BP1
To measure phosphorylated S6 and 4E-BP by intracellular flow cytometry, lineagedepleted bone marrow cells were treated with DMSO, 30 μM CHIR99021, 500 nM
rapamycin, or both at 37°C for times indicated. Cells were fixed and permeabilized as
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indicated by Cell Signaling Technology. Cells were stained for the surface markers
indicated and for pS6 conjugated to Pacific Blue (Ser235/236 [D57.2.2E], rabbit mAb,
final concentration 1:50, Cell Signaling Technology) and p4E-BP1 conjugated to PE
(Thr37/46 [236B4], rabbit mAb, final concentration 1:50, Cell Signaling Technology),
then analyzed by flow cytometry.
Assessment of rate of translation
Lineage-depleted cells were cultured as described above for 3 or 24 h, and then Opropargyl-puromycin (OP-Puro; Click-iT Plus OPP AlexaFluor 488 kit, Life Technologies)
was added (10 μM) to the medium for an additional 30 min. Cells were washed with PBS
and stained with LIVE/DEAD Fixable Near IR Dead Cell Stain (ThermoFisher) as directed
by the manufacturer. Cells were fixed in 0.5 ml of 1% paraformaldehyde (Electron
Microscopy Sciences) in PBS for 15 min covered on ice. Cells were washed in PBS, then
permeabilized in 200 μl PBS supplemented with 3% FBS and 0.1% saponin (Sigma) for
5 min at room temperature. The azide-alkyne cycloaddition was performed using the kit
as directed by the manufacturer. After the 30-min reaction, cells were washed in PBS
supplemented with 3% FBS, then stained for surface markers indicated and analyzed by
flow cytometry.
Mitochondrial analyses
Lineage-depleted cells were cultured as described above for 16 h and stained for
surface markers indicated. Mitochondrial mass and membrane potential were then
measured using MitoTracker Green FM (20 nM; Life Technologies) and MitoProbe JC-1
Assay Kit for Flow Cytometry (0.2 μM in X-VIVO 15; Life Technologies), respectively, as
indicated by the manufacturer and analyzed by flow cytometry.
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Immunofluorescence microscopy
LSK-SLAM cells were sorted as described above. Cells were cultured for 24 h as
described above, then fixed in 4% paraformaldehyde in PBS on glass slides for 30 min at
room temperature. Cells were washed twice in PBS, then permeabilized in 0.5% Triton X100 (ThermoFisher) in PBS for 10 min at room temperature. Cells were then washed twice
in PBS and blocked in 10% bovine serum albumin (BSA; Sigma-Aldrich) in PBS. Cells were
stained with rabbit anti-LC3 (1:500; MBL) in 5% BSA in PBS supplemented with 0.1%
TWEEN 20 (Sigma-Aldrich) for 1 h at room temperature and then overnight at 4°C. After
primary stain, cells were washed four times in PBS with 0.1% TWEEN 20. Secondary stain
was donkey anti-rabbit IgG conjugated to Alexa Fluor 555 (1:500; ThermoFisher) in 5%
BSA in PBS supplemented with 0.1% TWEEN 20, incubated for 1 h at room temperature
and protected from light, followed by four washes in PBS with 0.1% TWEEN 20. Cells were
counterstained with DAPI (1μg ml-1) in PBS for 5 min at room temperature and then
washed twice in PBS. Slides were mounted with ProLong Gold antifade reagent
(Invitrogen) and cured at room temperature for at least 24 h. Slides were imaged on an
Olympus IX81 fluorescent microscope setup with a Hamamatsu Camera Controller
C10600. Images were recorded and analyzed using the MetaMorph for Olympus Advanced
software.
Statistical methods
All data are depicted as mean +/- standard error of the mean (S.E.M.). Statistical
significance was assessed by one-way ANOVA, followed by post-hoc Tukey’s test or
Dunnett’s test for multiple comparisons as indicated. For pairwise comparisons,
significance was assessed by Student’s t-test.
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